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I. INTRODUCTION
The treatment of medical conditions during pregnancy is one of the
The resultant
least developed areas of clinical pharmacology. 1
uncertainty has a direct impact on patient care, leading to inappropriate
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1. See Catalin S. Buhimschi & Carl P. Weiner, Medications in Pregnancy and Lactation: Part
1. Teratology, 113 OBSTETRICS & GYNECOLOGY 166, 166 (2009). Medication use in breastfeeding
women is similarly understudied. Id. See also Esther E. Stultz et al., Extent of Medication Use in
Breastfeeding Women, 2 BREASTFEEDING MED. 145, 150 (2007) (finding that over a third of the
breastfeeding women surveyed took medications that were rated possibly or probably unsafe or were of
unknown safety).
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treatment and under treatment. The case of pregnant women infected
with the 2009 influenza A (H1N1) virus is instructive. Although
seasonal flu can cause severe illness during pregnancy, the “rapid
clinical deterioration” seen in some pregnant patients with H1N1 flu
appears to be unique. 2 While pregnant women make up approximately
1% of the United States population, they accounted for 5% of the deaths
caused by H1N1 in the United States in 2009. 3
As a result of H1N1’s potential to cause severe illness and death in
pregnant women, the Centers for Disease Control and Prevention (CDC)
recommended that they be among the first inoculated, 4 and that they
take the antiviral medications Tamiflu or Relenza at the first sign of flu
symptoms. 5 Dr. Denise Jamieson of the CDC told the New York Times
that “the benefit of giving Tamiflu outweighs the risk” for pregnant
patients who exhibit classic flu symptoms. 6 However, neither Tamiflu
nor Relenza is well-studied in pregnant women. 7 The authors of a New
York Times editorial point out that “[i]t is perfectly possible that the
standard adult dose of antivirals will not work in the pregnant body,” 8
and a group of experts convened by the CDC acknowledges that “[l]ittle
is known about the effects of the four currently available anti-influenza
medications on the fetus.” 9
The CDC has determined that in the early months of the pandemic
there was no delay in diagnosing pregnant women with the new flu

2. Janice K. Louie et al., Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in
California, 362 NEW ENG. J. MED. 27, 33 (2010).
3. Alicia M. Siston et al., Pandemic 2009 Influenza A(H1N1) Virus Illness Among Pregnant
Women in the United States, 303 JAMA 1517, 1522–23 (2010).
4. Id. at 1523.
5. Donald G. McNeil Jr., Drugs Urged for Swine Flu in Pregnancy, N.Y. TIMES, May 13, 2009,
at A10.
6. Id.
7. See Toshihiro Tanaka et al., Safety of Neuraminidase Inhibitors Against Novel Influenza
A(H1N1) in Pregnant and Breastfeeding Women, 181 CAN. MED. ASS’N J. 55, 56–57 (2009) (presenting
data derived from a Japanese post-marketing study that followed ninety pregnant women who took
Tamiflu in their first trimester, from a report by the manufacturer on sixty-one pregnant women exposed
to Tamiflu with unknown timing, from three cases of accidental exposure during clinical trials of
Relenza, and from “[a] study using an ex vivo human placenta model”); Highlights of Prescribing
Information for Relenza, http://us.gsk.com/products/assets/us_relenza.pdf (last visited Aug. 10, 2010);
Highlights of Prescribing Information for Tamiflu, http://www.rocheusa.com/products/tamiflu/pi.pdf
(last visited Aug. 10, 2010).
8. Ruth Faden et al., A Custom Drug, N.Y. TIMES, May 10, 2009, at WK10. See also Sonja A.
Rasmussen et al., Pandemic Influenza and Pregnant Women: Summary of a Meeting of Experts, 99 AM.
J. PUB. HEALTH S248, S250 (2009) (“No data are available to address whether dosage adjustment [of
anti-influenza medications] is needed; thus, no dosage alterations for pregnant women are recommended
at this time.”).
9. Rasmussen et al., supra note 8, at S249.
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strain. 10 In many cases, however, there was a delay in beginning
treatment with antiviral medication, 11 possibly because health care
providers, pregnant women, or both were reluctant to begin treatment
due to the lack of information about the effectiveness and safety of flu
medications during pregnancy. 12 This is unfortunate. A nationwide
study of pregnant women with H1N1 flu showed that women who did
not begin antiviral treatment until more than four days after symptom
onset were fifty-four times more likely to die than women who were
treated within two days of symptom onset. 13
The information gap is not unique to antivirals. We lack data on the
efficacy, safety, or both of most drugs when used by pregnant women. 14
This is a significant problem because an estimated two-thirds of the
women who give birth in the United States each year are prescribed a
drug other than a vitamin or mineral while they are pregnant. 15
Physiological changes caused by pregnancy, including a 30% to 40%
increase in blood flowing through the kidneys, “increases in blood
volume, decreases in gastric-emptying time, changes in the
concentrations of sex hormones, alterations in liver enzymes, [and] the
presence (to say the least) of a fetal-placental unit,” can affect the
absorption, distribution, and elimination of drugs rendering them more
or less efficacious. 16 For example, while the American College of
Obstetricians and Gynecologists recommends that pregnant women be
treated with amoxicillin in the event of anthrax exposure, recent
10. Denise J. Jamieson et al., H1N1 2009 Influenza Virus Infection During Pregnancy in the
USA, 374 THE LANCET 451, 456 (2009).
11. Id.; Louie et al., supra note 2, at 33. See also Allison L. Naleway et al., Delivering Influenza
Vaccine to Pregnant Women, 28 EPIDEMIOLOGIC REV. 47, 49 (2006) (reporting that pregnant women
had the lowest flu vaccine coverage level of all adult groups recommended to receive the vaccine,
perhaps due to their expressed concerns about vaccine safety). A recent study found a similar problem
with regard to antihypertensive drugs noting “site-specific differences” in the rate of use of such drugs to
treat pregnant women with high blood pressure. Susan E. Andrade et al., Outpatient Use of
Cardiovascular Drugs During Pregnancy, 17 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 240, 246
(2008). The researchers who conducted the study suggested that health care providers’ uncertainty
about how to manage hypertension during pregnancy given limited knowledge about the risk-to-benefit
profile of the various medications could explain the treatment differences. Id.
12. Jamieson et al., supra note 10, at 456.
13. Siston et al., supra note 3, at 1521.
14. Anne Drapkin Lyerly et al., The Second Wave: Toward Responsible Inclusion of Pregnant
Women in Research, 1 INT’L J. OF FEMINIST APPROACHES TO BIOETHICS 6, 7 (2008); Allen A. Mitchell,
Systematic Identification of Drugs that Cause Birth Defects – A New Opportunity, 349 NEW ENG. J.
MED. 2556, 2556–57 (2003) (explaining that “the vast majority of medications currently in use have not
been studied in a way that would reveal moderate teratogenic risks,” which the author defines as a risk
two to ten times greater than the base-line risk for a specific birth defect).
15. Susan E. Andrade et al., Prescription Drug Use in Pregnancy, 191 AM. J. OBSTETRICS &
GYNECOLOGY 398, 400 (2004).
16. Lyerly et al., supra note 14, at 8.
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pharmacokinetic research indicates that changes to kidney function
during pregnancy may make it impossible to give a pregnant woman a
high enough dose of the antibiotic for it to be effective against anthrax. 17
Similarly, blood concentrations of antimalarial and diabetes drugs have
been shown to be reduced in pregnant women such that higher doses
than are currently recommended are needed. 18
Pregnancy also creates special safety concerns. Because most drugs
pass from the mother’s blood through the placenta to the fetus, a
pregnant woman deciding to take a drug needs to know its potential to
cause teratogenic harm. 19 Teratogens are “agents that act to irreversibly
alter growth, structure, or function of the developing embryo or fetus.” 20
They include certain chemicals (e.g., alcohol, mercury), environmental
conditions (e.g., heat, radiation), and viruses (e.g., cytomegalovirus,
rubella) as well as some therapeutic drugs. 21 Complicating matters, a
drug’s teratogenic and other ill effects can vary by gestational age.
During the period of organogenesis, which occurs between three and
eight weeks after fertilization, each organ system has a period of peak
vulnerability. 22 For example, spina bifida and related defects arise
during the process of neurulation, which occurs between seventeen and
thirty days after fertilization. 23 The heart is most vulnerable between six
and a half and eight weeks of gestation. 24
Nonsteroidal antiinflammatory drugs like aspirin and ibuprofen can cause, among other
problems, the abdominal wall defect gastroschisis when taken in early
pregnancy; in late pregnancy, they can cause premature closure of the
ductus arteriosus, a heart defect. 25 A recently published study suggested
that in the case of serotonin reuptake inhibitors, a widely prescribed
class of antidepressant medication, the timing of in utero exposure may
17. American College of Obstetricians and Gynecologists, Management of Asymptomatic
Pregnant or Lactating Women Exposed to Anthrax, 77 INT’L J. GYNECOLOGY & OBSTETRICS 293, 294–
95 (2002); Anne Drapkin Lyerly et al., The National Children’s Study: A Golden Opportunity to
Advance the Health of Pregnant Women, 99 AM. J. PUB. HEALTH 1742, 1742 (2009) (citing M.A.
Andrew et al., Amoxicillin Pharmacokinetics in Pregnant Women: Modeling and Simulations of Dosage
Strategies, 81 CLINICAL PHARMACOLOGY & THERAPEUTICS 547, 547–56 (2007)).
18. Lyerly et al., supra note 17, at 1742 (citing M.F. Herbert et al., Are We Optimizing
Gestational Diabetes Treatment with Glyburide? The Pharmacologic Basis for Better Clinical Practice,
85 CLINICAL PHARMACOLOGY & THERAPEUTICS 607, 607–14 (2009)); Nicholas J. White et al., New
Medicines for Tropical Diseases in Pregnancy: Catch-22, 5 PLOS MED. 843, 843 (2008).
19. Catalin S. Buhimschi & Carl P. Weiner, Medications in Pregnancy and Lactation: Part 1.
Teratology, 113 OBSTETRICS & GYNECOLOGY 166, 167 (2009).
20. Id. at 167.
21. Id.
22. Id. at 168.
23. Id.
24. Id.
25. Id.
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be less important than the duration. 26
Our profound ignorance about what drug to use and when to use it has
a number of negative repercussions. On the one hand, of necessity
health care providers prescribe medications to pregnant women “offlabel,” that is, without FDA-approved dosing or other guidance; for
some of these drugs, the risk of harm outweighs any potential for
therapeutic gain. 27 On the other hand, the lack of data leads to “lost
therapeutic opportunities.” 28 It causes some health care providers to
recommend that pregnant women forego needed treatment that would,
on balance, reduce the risk of harm to them and their fetuses. 29 It causes
other health care providers to choose older medications they believe to
be safe over newer drugs that may have important therapeutic or safety
advantages for pregnant women and their fetuses. 30 The information
gap also results in medications being prescribed in doses too low to be
effective or higher than necessary to achieve a therapeutic benefit while
minimizing the risk of fetal harm. 31 Finally, when a fetus is
inadvertently exposed to medication in early pregnancy, terminating the
pregnancy may be considered. 32 An unknown risk of birth defects could
cause some women to terminate wanted pregnancies. 33
While many medical decisions could benefit from better
information, 34 the lack of data about the treatment of medical conditions

26. Tim F. Oberlander et al., Effects of Timing and Duration of Gestational Exposure to
Serotonin Reuptake Inhibitor Antidepressants: Population-Based Study, 192 BRIT. J. PSYCHIATRY 338,
341–42 (2008).
27. Lyerly et al., supra note 14, at 10–11.
28. Barbara A. Noah, Just a Spoonful of Sugar: Drug Safety for Pediatric Populations, 37 J.L.
MED. & ETHICS 280, 281 (2009) (discussing the lack of information about the safety and efficacy of
drugs when used in pediatric populations).
29. Lyerly et al., supra note 14, at 11–13.
30. See, e.g., Michelle Meadows, Pregnancy and the Drug Dilemma, 35 FDA CONSUMER 16, 18
(2001) (quoting Catherine Stika, a physician and assistant professor of obstetrics and gynecology at
Northwestern University School of Medicine, as follows: “We’ll prescribe an older hypertension drug
because its long history hasn’t turned up serious safety concerns. . . . There may be other drugs that are
more effective and better tolerated, but we don’t use them because we don’t know about their safety.”).
31. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,844 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201).
32. Id. at 30,834.
33. Id. See also Gideon Koren et al., Drugs in Pregnancy, 338 NEW. ENG. J. MED. 1128, 1134
(1998) (“Women often report that their physicians have encouraged them to terminate otherwise wanted
pregnancies just to be on the safe side, suggesting that many physicians are unfamiliar with the current
literature on the safety of drugs taken during pregnancy.”). Cf. Anne Drapkin Lyerly et al., Risk and the
Pregnant Body, HASTINGS CENTER REP., Nov.–Dec. 2009, at 34, 36 (discussing a study in which 5% of
obstetricians and family physicians surveyed reported that they would recommend abortion to patients
who had a radiologic scan in early pregnancy based on their (mistaken) perceptions of teratogenic risk).
34. See Lars Noah, Medicine’s Epistemology: Mapping the Haphazard Diffusion of Knowledge
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during pregnancy is particularly troubling. The medical decisions that
pregnant women and their health care providers make are complicated
by the fact that they must account for two interdependent patients
instead of the usual one, and the stakes are high. In addition, as Anne
Drapkin Lyerly and her co-authors have noted, there is reason to
question our ability to reason about risk during pregnancy. 35 Women
and their health care providers have been shown to overestimate the risk
that drugs will cause serious birth defects. 36 Lyerly, a practicing
obstetrician, writes that “[w]hen treating pregnant women’s
nonobstetrical medical needs, it turns out, there is a tendency to notice
the risks of intervening without adequately noting the risks of failing to
intervene.” 37 She concludes that in pregnancy “a particularly unfettered
version of the precautionary principle” too often replaces evidencebased recommendations. 38 The cultural norm of purity in pregnancy and
our reluctance to confront potential trade-offs between maternal and
fetal interests further hinder our ability to reason about medication risk
and pregnancy. 39 While Lyerly and her colleagues argue that maternal–
fetal interests are more often aligned than not, conflicts can occur. 40 All
of these factors make it especially important that treatment decisions in
pregnancy not be made in ignorance.
A frequent shorthand explanation for the dearth of information about
the safety and efficacy of drugs when used during pregnancy is that you
cannot test drugs on pregnant women because of ethical concerns. 41
Real moral conundrums arise in maternal–fetal medicine and there will
always be information that is out of reach because it can only be gleaned
from clinical trials that are ethically impermissible. 42 This alone does
in the Biomedical Community, 44 ARIZ. L. REV. 373, 389 (2002) (“[N]o one denies that many medical
treatments remain seriously understudied.”).
35. Lyerly et al., supra note 33, at 35.
36. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,844 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201) (citing sources).
37. Anne Drapkin Lyerly et al., Risk and the Pregnant Body, HASTINGS CENTER REP., Nov.–
Dec. 2009, at 35.
38. Id. at 39.
39. Id.
40. Id. at 40.
41. See, e.g., Liz Szabo, A ‘Drug Drought’ for Pregnant Women, USA TODAY, June 3, 2008,
available at http://www.usatoday.com/news/health/2008-06-03-pregnant-drugs_N.htm (reporting that
Alan Goldhammer, deputy vice president of regulatory affairs for PhRMA, the trade organization which
represents many pharmaceutical and biotechnology companies, said that although drug makers would
like to develop drugs for pregnancy complications, they have to consider the potential harmful effects
that experimental drugs could have on a fetus).
42. Lyerly et al., supra note 17, at 2. See also The Am. Coll. of Obstetricians & Gynecologists
Comm. on Ethics, Ethical Considerations in Research Involving Pregnant Women, 65 INT’L J.
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not explain the information gap. First, not all clinical trials in pregnant
women are unethical. 43 Second, data derived from other types of
investigations that are ethically unproblematic, for example,
pharmacokinetic studies in pregnant women taking a medication as part
of their prescribed treatment regimen, are also lacking, as are
epidemiological data.
Existing statutory and regulatory levers do elicit private-sector drug
research, the research required to monetize a patent, for example, along
with the research necessary to secure permission to sell a prescription
drug, to market an approved drug for a heretofore unapproved use, and
to make certain promotional claims about a drug. However, they do not
generate adequate research into the safety and efficacy of drugs when
used during pregnancy. Because these levers hinge on the existence of
profitable potential markets for the drugs studied, they ill-serve the
relatively small and transient pregnant patient population. Federal
regulations and guidance that affirmatively limit the testing of drugs in
pregnant women for ethical and other reasons further slow the pace of
maternal–fetal medication research.
The common law fails to fill the information gap. A company has an
incentive to study a drug to the extent that detecting safety issues early
reduces the number of injuries caused by that drug and, therefore, the
company’s exposure to damage awards. Companies must also consider
the risk of liability for failing to warn of risks for which they
unreasonably failed to test. These incentives are weighed against
companies’ exposure to liability for harms incurred by research
participants. Moreover, when research reveals that a drug previously
believed to be safe in fact causes harm, lawsuits inevitably follow. This
is true even in cases where the company acted responsibly. Finally,
many observers believe that maternal–fetal medication research is
especially susceptible to a “liability barrier,” because of the high
GYNECOLOGY & OBSTETRICS 93 (1999).
43. See Laurence B. McCullough et al., A Comprehensive Ethical Framework for Responsibly
Designing and Conducting Pharmacologic Research that Involves Pregnant Women, 193 AM. J.
OBSTETRICS & GYNECOLOGY 901 (2005). The medical literature provides multiple examples of
placebo-controlled studies in pregnant women, suggesting that there are circumstances in which the riskbenefit ratio of such research is favorable. See, e.g., Mark B. Landon et al., A Multicenter, Randomized
Trial of Treatment for Mild Gestational Diabetes, 361 NEW ENG. J. MED. 1339, 1339 (2009); Dwight J.
Rouse et al., A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral
Palsy, 359 NEW ENG. J. MED. 895, 895 (2008); Debra A. Guinn et al., Terbutaline Pump Maintenance
Therapy for Prevention of Preterm Delivery: A Double-Blind Trial, 179 AM. J. OBSTETRICS &
GYNECOLOGY 874 (1998); Debra A. Guinn et al., Management Options in Women with Preterm Uterine
Contractions: A Randomized Clinical Trial, 177 AM. J. OBSTETRICS & GYNECOLOGY 814 (1997); see
also Steve Sternberg, Pregnant Women Taking Part in New H1N1 Vaccination Trials, USA TODAY,
Sept. 10, 2009, available at http://www.usatoday.com/news/health/2009-09-10-pregnant-swine-fluvaccine_N.htm.
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background rate of birth defects, because of the potential for large
damage awards, and because of the “long tail” of associated litigation.
This Article proceeds as follows. Part II assesses our current state of
ignorance about the safety and efficacy of drugs when used during
pregnancy. Part III sets forth the existing statutory and regulatory levers
to elicit private-sector drug research and explains why neither they nor
the tort system generate sufficient maternal–fetal medication research.
Part IV evaluates two oft-mentioned policy responses to an
underproduction of medical research, (1) eliminating (or muting the
effect of) the liability barrier facing pharmaceutical companies and (2)
offering an extended period of exclusivity to incentivize private-sector
research, and concludes that both are, on balance, undesirable
approaches to increasing our understanding of maternal–fetal medication
risk.
Instead, Part IV recommends that federal and state governments
increase their support for maternal–fetal medication research, including
through innovative public-private partnerships like the FDA’s recently
announced Medication Exposure in Pregnancy Risk Evaluation
Program 44 and its Sentinel System. 45 Industry can and should do more
as well. Congress should require pharmaceutical companies to conduct
an assessment of maternal–fetal medication risk as part of the new drug
approval process, and it should empower the FDA to require that
companies study their already-approved drugs in pregnant women, steps
that have already been taken in the pediatric arena. In the meantime, the
FDA should make full use of its existing authority to require postmarketing surveillance, including the establishment of pregnancy
registries, as a condition of drug approval and to require manufacturers
to conduct post-marketing studies and clinical trials when questions
arise about the safety of their drugs in pregnant women.
II. THE MATERNAL–FETAL MEDICATION RISK INFORMATION GAP
The dearth of information about the treatment of medical conditions
during pregnancy is a significant problem. In the United States, there
are over sixty million women of childbearing age, defined for statistical
purposes as between the ages of fifteen and forty-four. 46 More than nine

44. Press Release, U.S. Dept. of Health & Human Servs., Food & Drug Admin., Health
Organizations to Study Safety of Medications Taken During Pregnancy (Dec. 30, 2009), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm195934.htm.
45. U.S. DEPT. OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., FDA’S SENTINEL
INITIATIVE, http://www.fda.gov/Safety/FDAsSentinelInitiative/default.htm (last visited Aug. 12, 2010).
46. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
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million of them have chronic conditions that require ongoing
prescription drug treatment during pregnancy to protect their health and
the health of their fetuses. 47 Millions more develop a new medical
condition or experience the exacerbation of an old one while they are
pregnant. 48
Asthma, for example, is prevalent in pregnancy, afflicting
approximately 8% of pregnant women. 49 There is a strong association
between poor asthma control during pregnancy and health problems for
the baby, including intrauterine growth restriction, preeclampsia,
preterm birth, low birth weight, birth defects, and perinatal death.50
Poor asthma control during pregnancy also has a direct effect on the
pregnant woman, increasing serious risks to her health and life. 51
Despite these findings, only two randomized controlled trials involving
pregnant women with asthma have been conducted, and, as a result, the
“mechanisms linking poorly controlled asthma to adverse perinatal
outcomes remain unclear.” 52
Diabetes diagnosed prior to and during pregnancy is also common—
occurring in just over 4% of pregnancies that end in birth. 53 Diabetes is
becoming increasingly prevalent during pregnancy; since 2003, it has
increased at a rate of 6–7% per year. 54 Pregnancy-induced hypertension
is common too, occurring in just under 4% of pregnancies, while chronic
hypertension complicates another 1% of pregnancies. 55 Like the
diabetes rate, the hypertension rate during pregnancy has been
increasing every year in recent years. 56 One possible explanation is the
rise in the pregnancy and birth rate among women forty years of age and
older, as the proportion of women receiving an antihypertensive

Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,844 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201).
47. Id.
48. Id. at 30,841 (noting that depression and migraine headaches can be exacerbated by
pregnancy).
49. Michael Schatz & Mitchell P. Dombrowski, Asthma in Pregnancy, 360 NEW ENG. J. MED.
1862, 1862 (2009).
50. Id.
51. Id.
52. Id. at 1864, 1866. Conducting controlled trials “to determine the effects of asthma control, as
compared with lack of control, on perinatal outcomes” is not possible due to ethical concerns. Id. at
1866.
53. Joyce A. Martin et al., Ctrs. for Disease Control & Prevention, Nat’l Vital Statistics Reports,
Births: Final Data for 2006, Jan. 7, 2009, at 13, available at http://www.cdc.gov/nchs/data/nvsr/
nvsr57/nvsr57_07.pdf.
54. Id.
55. Id. at 14.
56. Id.
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medication increases with age. 57 Other diseases occurring during
pregnancy include autoimmune diseases, cancer, epilepsy, and
psychiatric illness, which complicates an estimated 500,000
pregnancies. 58
More than four million women give birth in the United States each
year 59 and many of them take medication during their pregnancies. A
2004 study conducted by Susan Andrade and colleagues of the
electronic medical records of over 150,000 women located throughout
the United States who received prenatal care between 1996 and 2000
revealed that 64% were dispensed at least one medication other than a
vitamin or mineral supplement. 60 A 2003 study in which close to six
hundred rural obstetric patients in West Virginia were interviewed on
multiple occasions about medication use found that, excluding prenatal
vitamins and minerals, about 60% took a prescription medication during
their pregnancy. 61
There is also unintended drug use during pregnancy. Every year, an
estimated 10% of women between the ages of fifteen and forty-four
become pregnant; 62 nearly half of these pregnancies are unplanned. 63 A
2002 survey found that 82% of women eighteen to forty-four years old
had used some type of medication during the preceding week, 46% used
a prescription drug, and 3% used five or more prescription drugs. 64 As

57. Andrade et al., supra note 11, at 243.
58. Lyerly et al., supra note 14, at 6 (reporting that autoimmune diseases and cancer “commonly
occur with pregnancy and often require treatment”); Pamela Paul, With Child, With Cancer, N.Y. TIMES,
Aug. 31, 2008, at MM34 (reporting that the estimated rate of pregnancy-associated cancer is 1 in 1000);
Torbjörn Tomson, Which Drug for the Pregnant Woman with Epilepsy?, 360 NEW. ENG. J. MED. 1667,
1667 (2009) (noting that approximately 25,000 children are born to mothers with epilepsy each year and
that most women with epilepsy must continue taking medication to treat it during pregnancy);
AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS, ACOG PRACTICE BULLETIN NO. 92,
USE OF PSYCHIATRIC MEDICATIONS DURING PREGNANCY AND LACTATION (2008).
59. Stephanie J. Ventura et al., Ctrs. for Disease Control & Prevention, Nat’l Vital Statistics
Reports, Estimated Pregnancy Rates by Outcome for the United States, 1990–2004, Apr. 14, 2008, at 1,
available at http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_15.pdf.
60. Susan E. Andrade et al., Prescription Drug Use in Pregnancy, 191 AM. J. OBSTETRICS &
GYNECOLOGY 398, 400 (2004).
61. Douglas D. Glover et al., Prescription, Over-the-Counter, and Herbal Medicine Use in a
Rural, Obstetric Population, 188 AM. J. OBSTETRICS & GYNECOLOGY 1039, 1041 (2003).
62. Ventura et al., supra note 59, at 12. There are approximately six million pregnancies per
year in the United States. Press Release, U.S. Dept. of Health & Human Servs., Food & Drug Admin.,
FDA Proposes New Rule to Provide Updated Information on the Use of Prescription Drugs and
Biological Products during Pregnancy and Breast-feeding (May 28, 2008), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116902.htm.
63. CTRS. FOR DISEASE CONTROL & PREVENTION, PREGNANCY RISK ASSESSMENT MONITORING
SYSTEM (PRAMS): PRAMS AND UNINTENDED PREGNANCY, http://www.cdc.gov/prams/PDFs/
PRAMSUnintendPreg.pdf (last visited Feb. 27, 2010).
64. David W. Kaufman, et al., Recent Patterns of Medication Use in the Ambulatory Adult
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these statistics suggest, many women unwittingly expose their fetuses to
one or more medications before realizing that they are pregnant. 65 Such
exposure typically occurs in the critical window between three and eight
weeks after conception when the fetus’ organs develop. 66
The FDA approves most drugs without any evidence of safety or
efficacy when used during pregnancy. 67 The situation does not improve
post-approval, as evidenced by the fact that 60% of prescription drugs
are classified by the FDA as category C, 68 indicating either that (1) a
drug has not been studied in either pregnant animals or pregnant women
or that (2) adequate and well-controlled studies in pregnant women have
not been conducted, animal studies show the drug poses a risk to the
fetus, but the drug’s benefits may outweigh the potential risk. 69 Less
Population of the United States: The Slone Survey, 287 JAMA 337, 339 (2002).
65. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,841 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201). While inadvertent exposure most commonly occurs in early
pregnancy, it can occur at any stage. Id.
66. Id.
67. Id.; Caroline T. Lagoy et al., Medication Use During Pregnancy and Lactation: An Urgent
Call for Public Health Action, 14 J. WOMEN’S HEALTH 104, 105 (2005).
68. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,834 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201).
69. Under the current regulations, prescription drug labels must include a “Pregnancy” section
with information about the drug’s potential to cause birth defects as well as any other reproductive
effects. Id. at 30,832. Each product is assigned a letter—A, B, C, D, or X—based on its potential to
cause reproductive and developmental adverse effects. Id. at 30,832–33. For categories C, D, and X, a
drug’s potential to cause harm is weighed against its potential benefit, meaning that the only difference
between a drug in category X and a drug in category D could be that there is a safer alternative to the
drug in category X. See id. at 30,833. The five categories are defined as follows. A drug is category A
if adequate and well-controlled studies have been conducted in pregnant women and shown no “risk to
the fetus in the first trimester of pregnancy (and there is no evidence of a risk in later trimesters).” 21
C.F.R. § 201.57(c)(9)(i)(A)(1) (2010). A drug is category B if animal studies have been conducted and
shown no risk but there are no adequate and well-controlled studies in pregnant women, or if animal
studies have shown a risk but adequate and well-controlled studies in pregnant women have been
conducted and did not show a risk. Id. § 201.57(c)(9)(i)(A)(2). Category C covers drugs the risks of
which have not been studied in pregnant animals or pregnant women; it also covers drugs that animal
studies have shown pose a risk to the fetus and that have not been studied in pregnant women, if the
drug’s benefits may outweigh its potential risks. Id. § 201.57(c)(9)(i)(A)(3). Category D is used:
If there is positive evidence of human fetal risk based on adverse reaction data from
investigational or marketing experience or studies in humans, but the potential benefits
from the use of the drug in pregnant women may be acceptable despite its potential risks
(for example, if the drug is needed in a life-threatening situation or serious disease for
which safer drugs cannot be used or are ineffective).
Id. § 201.57(c)(9)(i)(A)(4). Finally, category X is for drugs for which the risk of use in pregnant woman
clearly outweighs any possible benefit. Id. § 201.57(c)(9)(i)(A)(5). In 2008, the FDA issued proposed
amendments to the pregnancy labeling regulations which would abolish the category system and replace
it with a narrative format that the agency believes would better capture the “complexity of medical
decisionmaking about drug use during pregnancy.” Content and Format of Labeling for Human

Published by University of Cincinnati College of Law Scholarship and Publications, 2011

11

University of Cincinnati Law Review, Vol. 79, Iss. 1 [2011], Art. 6
GREENWOOD FINAL FORMAT 3

278

2/14/2011 5:48:25 PM

UNIVERSITY OF CINCINNATI LAW REVIEW

[Vol. 79

than 1% of drugs fall into category A, which is reserved for drugs the
safety of which has been demonstrated by adequate and well-controlled
studies in pregnant women. 70 In 2002, researchers found that the risks
posed to the fetus by more than 90% of the prescription drugs approved
in the United States between 1980 and 2000 remained unknown. 71 The
same researchers found that it took an average of six years after FDA
approval for drugs posing a substantial teratogenic risk to be recognized
as dangerous, and an average of nine years after FDA approval for drugs
posing no more than a minimal teratogenic risk to be recognized as
safe. 72
Many of the drugs used by pregnant women have not been shown to
be safe or have been associated with a risk of fetal harm. The 2004
Andrade research revealed that 37.8% of the women studied were
prescribed a drug from category C while pregnant, 4.8% from category
D, indicating that there is evidence the drug could cause fetal harm but
the benefits may outweigh the risk, and 4.6% from category X,
indicating that the risk of use during pregnancy clearly outweighs any
possible benefit. 73 Andrade and colleagues also analyzed a sub-group of
129,616 deliveries and found that, after excluding contraceptives and
other hormones, which may be classified as category D or X but which
the evidence suggests are unlikely to have teratogenic effects, 74 and
drugs used to treat infertility, which may similarly be classified as D or
X but which are continued through early pregnancy under some
protocols, 75 3% of pregnant women received at least one dispensing of a
category D or X drug. 76 Another study of the electronic medical records
Prescription Drugs and Biological Products; Requirements for Pregnancy and Lactation Labeling, 73
Fed. Reg. 30,831, 30,838 (proposed May 29, 2008) (to be codified at 21 C.F.R. pt. 201). On April 26,
2010, the Department of Health & Human Services announced that the FDA would release the final
regulation by March 2011. Semiannual Regulatory Agenda, 75 Fed. Reg. 21,782, 21,795 (Apr. 26,
2010).
70. Buhimschi & Weiner, supra note 1, at 170.
71. W.Y. Lo & J.M. Friedman, Teratogenicity of Recently Introduced Medications in Human
Pregnancy, 100 OBSTETRICS & GYNECOLOGY 465, 468 (2002).
72. Id. at 472.
73. Andrade et al., supra note 15, at 400. In addition, 2.1% received a drug unrated by the FDA.
Id.
74. Susan E. Andrade et al., Use of Prescription Medications with a Potential for Fetal Harm
Among Pregnant Women, 15 PHARMACOEPIDEMIOLOGY & DRUG SAFETY 546, 551 (2006) (noting that
the “preponderance of data now suggests unlikely teratogenic potential” for oral contraceptives). Oral
contraceptives are used during the early part of about 1% of pregnancies. Buhimschi & Weiner, supra
note 1, at 181 (noting that this estimate may be low because the authors did not evaluate drug use in
pregnancies that did not go to term whether due to abortion or miscarriage).
75. Erika Hyde Riley et al., Correlates of Prescription Drug Use During Pregnancy, 14 J.
WOMEN’S HEALTH 401, 402–03 (2005).
76. Andrade et al., supra note 15, at 400.
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of over 100,000 women who received prenatal care during the same time
period found that 3.6% were prescribed a drug in category D while
pregnant and 2.4% a drug in category X. 77 A smaller study of 1,626
women who were pregnant between 2001 and 2003 found that 3.9%
were prescribed a category D or X drug other than progestins, which are
used to treat infertility. 78 Finally, a study of data from the National
Ambulatory Medical Care and National Hospital Ambulatory Medical
Care Survey found that 6.4% of office visits made by pregnant women
in 1999 and 2000 were associated with the prescription, provision, or
continuation of a category D or X drug. 79
Studies from other countries have also shown high levels of use of
drugs with established or potential fetal risk, including a study of nearly
82,000 British women who were pregnant between 1991 and 1999,
which found that in the first trimester 34.5% were prescribed a category
C drug, 1.6% a category D drug, and 1.0% a category X drug. 80 A study
of over 18,000 Canadian woman who gave birth between 1997 and 2000
showed that one in five pregnant women used a drug with established or
unknown fetal risk that the FDA has classified as category C, category
D, or category X. 81 Another widely cited study tracked all of the
original prescriptions issued throughout the pregnancies of 1,000 women
in 1996 in southwest France and found that 59% were prescribed a
category D medication and that 1.6% were prescribed one or more
category X medications. 82 Nearly 80% were exposed to drugs that were
uncategorized by the FDA and for which there is no evidence of safety
in pregnancy. 83
The evidence that large numbers of pregnant women are prescribed
77. Andrade et al., supra note 74, at 549. This study also included an evaluation by an expert in
teratogenecity who found that 1.1% of pregnant women received a teratogenic drug after their first
prenatal care visit and that 0.3% received four or more dispensings of a known teratogen. Id.
78. Riley et al., supra note 75, at 404.
79. Euni Lee et al., National Patterns of Medication Use During Pregnancy, 15
PHARMACOEPIDEMIOLOGY & DRUG SAFETY 537, 540 (2006).
80. Janet R. Hardy et al., Safety of Medications Prescribed Before and During Early Pregnancy
in a Cohort of 81,975 Mothers from the UK General Practice Research Database, 15
PHARMACOEPIDEMIOLOGY & DRUG SAFETY 555, 562 (2006).
81. S.W. Wen et al., Patterns of Pregnancy Exposure to Prescription FDA C, D and X Drugs in
a Canadian Population, 28 J. PERINATOLOGY 324 (2008). Among this study’s disturbing findings is the
fact that trimethoprim/sulfamethoxazole was the antibiotic most frequently prescribed to pregnant
women. Id. at 327. Trimethoprim/sulfamethoxazole is a folic acid antagonist that can cause birth
defects and other problems in newborns. Id. There are alternative antibiotics which are equally
effective. Id. This suggests that generating safety and efficacy information is only one piece of a larger
puzzle. In addition to information gaps, there are dissemination gaps.
82. I. Lacroix et al., Prescription of Drugs During Pregnancy in France, 356 THE LANCET 1735,
1735–36 (2000).
83. Id. at 1736.
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drugs that are known to be harmful could be evidence of calculated risks
taken by women and their health care providers, 84 or of provider error or
ignorance. 85 The widespread use of prescription drugs of unknown risk,
on the other hand, is evidence of an information gap.
III. EXISTING LEGAL AND REGULATORY LEVERS TO ELICIT PRIVATESECTOR DRUG RESEARCH
As Rebecca Eisenberg has observed, the social value of better
information about the efficacy and safety of prescription drugs greatly
exceeds the value of that information to the private firms which
manufacture the drugs. 86 When clinical trials and other informationgenerating activities reveal that a drug is more effective or safer than
previously believed, only some of the value generated can be recouped
by the firm. When the news is bad, the firm recoups nothing. Patients
benefit, as can health care providers, payors (including the government),
and firms that sell substitute drugs, but the company that sponsored the
research does not benefit and is in fact harmed. 87 A company that
studies one of its already-approved drugs risks “generating results that
could destroy the value of the product rather than enhance it.” 88
Benjamin Roin has suggested that there is also a disconnect on the cost
side of the equation, with sponsoring companies internalizing clinical
trial costs in excess of the trials’ costs to society.89 This could occur
when a sponsor bears the cost of study participants’ medical care. 90
For these reasons, motivating firms to study their drugs is “a major
challenge for the legal system.” 91 Below I discuss four legal regimes
that affect firms’ incentives to invest in information development: (1)
patents; (2) the FDA approval process, including FDA-administered
84. Riley et al., supra note 75, at 408 (“Although the prenatal use of many of the category D and
X drugs identified in our analysis may place women or their unborn children at unnecessary risk, some
of these drugs may have been prescribed after careful consideration that benefits outweigh the risks.”).
85. See id. at 401 (noting that there are safer alternatives for many of the category D and X
medications that pregnant women are prescribed); Noah, supra note 34, at 377 (“[W]e already have
evidence-based medicines, but we most certainly do not yet enjoy fully evidence-based medical
practice.”).
86. Rebecca S. Eisenberg, The Problem of New Uses, 5 YALE J. HEALTH POL’Y L. & ETHICS
717, 718 (2005).
87. Id.
88. Id. This risk may be lessened in the maternal–fetal context, because a finding that a drug is
unsafe for use during pregnancy could leave its broader market unaffected.
89. Benjamin N. Roin, Unpatentable Drugs and the Standards of Patentability, 87 TEX. L. REV.
503, 563 (2009).
90. Id.
91. Eisenberg, supra note 86, at 719–20.
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periods of exclusivity that can supplement the patent regime’s market
exclusivity period, the pre-approval reproductive toxicity testing the
agency requires, and the ethical limits the agency places on testing drugs
in pregnant women; (3) the FDA’s regulation of pharmaceutical
marketing and the incentive it creates for companies to conduct research
into “off-label” drug uses; and (4) the tort system. 92
A. Research Required to Monetize a Drug Patent
As Eisenberg observes, “[d]rugs are information-rich chemicals that
in many respects are more akin to other information products (such as
databases) than they are to other chemicals (such as industrial
solvents).” 93 In the absence of information about their safety and
efficacy in humans, drugs would not be drugs, and there would be no
market for them. Firms must invest in information development to
create a market for their drugs, but would not do so if competitor firms
could immediately free ride on their investment. 94 By excluding wouldbe free riders from the market for twenty years, the patent regime sets
the stage for pharmaceutical firms to profit from the costs of establishing
a drug’s safety and efficacy for a particular use. 95
The protection the patent regime provides for firms’ investment in
research into new uses for existing drugs, including their use in specific
subpopulations, is much weaker. While a firm can secure a patent for a
new use, this would not stop competitors from manufacturing and
selling the drug for the old use. 96 In theory, the innovator firm could sue

92. Firms are, of course, also subject to a host of other incentives unrelated to the legal regimes
discussed. To give just one example, insurance reimbursement may be conditioned on scientifically
sound safety and efficacy evidence. See Stephen Siciliano, Randomized Clinical Trial Said Needed to
Gain Payment for Novel Therapeutic, 4 LIFE SCI. L. & INDUS. REP. 236, 236 (2010). Cf. AETNA,
CLINICAL POLICY BULLETIN: TERBUTALINE PUMP FOR PRETERM LABOR, http://www.aetna.com/cpb/
medical/data/400_499/0468.html (last visited Apr. 30, 2010) (summarizing the existing evidence on the
use of the asthma medication terbutaline off-label for preventing or treating preterm labor and
determining that the use was “experimental and investigational,” that is, unlikely to be reimbursed).
93. Eisenberg, supra note 86, at 717.
94. Id. at 721; Kevin Outterson, Pharmaceutical Innovation: Law & the Public’s Health, 37 J.L.
MED. & ETHICS 173, 173 (2009) (“While empirical research suggests that patents are an ineffective
incentive for innovation generally, patents retain their paradigmatic function in the pharmaceutical and
chemistry industries.”).
95. Eisenberg, supra note 86, at 721.
96. Id. at 724. But see Novo Nordisk A/S v. Caraco Pharm. Labs., Ltd., 601 F.3d 1359, 1365
(Fed. Cir. 2010) (“This court perceives that the Hatch-Waxman Act will thus ensure that a generic drug
for non-patented purposes will not be used for patented purposes via a simple section viii certification.
Instead, the generic manufacturer will need to alleviate the risk of infringement or induced infringement
in a proceeding that fully tests for infringement and its implications, including potential health and
safety risks.”).
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any generic manufacturer who promotes the drug for the new, infringing
use, as well as the doctors, pharmacists, and patients who prescribe,
dispense, and take the drug. This avenue is undesirable for a number of
reasons, including that “few industries prosper by suing customers.” 97
Research into the safety and efficacy of a new drug when used during
pregnancy is not required to create a market for the drug and thereby
monetize the asset. For example, a drug that treats diabetes or
hypertension need only be shown effective at stabilizing blood sugar or
blood pressure for there to be a market for it. Its efficacy and safety in
pregnancy can remain unknown.
The failure of the patent regime to incentivize the development of
drug treatments for pregnancy-specific conditions such as miscarriage,
intrauterine growth restriction, preeclampsia, placental abruption, and
preterm birth is a related but distinct problem, one that this Article does
not address. Briefly, despite the devastation these conditions cause,
obstetric drug development proceeds at a glacial pace. 98 The FDA has
not approved a new class of drugs to treat pregnancy complications for
two decades, and as there are no first-generation drugs in clinical trials
now, none is likely to be approved for at least another decade. 99
B. Research Required for Permission to Sell a Prescription Drug
The patent regime’s incentive to conduct research and development is
supplemented by the federal Food, Drug, and Cosmetic Act (FD&C Act)
requirement that prescription drugs be approved by the FDA before they

97. Eisenberg, supra note 86, at 724.
98. Obstetrics has been called the “‘the least scientific specialty in medicine,’” in part because
the mainstays of its drug formulary “hark back to an earlier era.” Nicholas M. Fisk & Rifat Atun,
Market Failure and the Poverty of New Drugs in Maternal Health, 5 PLOS MED. 22, 22 (2008). See
also ATUL GAWANDE, BETTER: A SURGEON’S NOTES ON PERFORMANCE 188 (2007). A recent study
which compared drug development in maternal health with the drug pipelines for cardiovascular disease,
a mainstream but not leading specialty area, and amyotrophic lateral sclerosis, an orphan disease
afflicting just 20,000 patients in the seven main drug markets, found that there are only seventeen drugs
under development in obstetrics, compared to six hundred sixty in cardiovascular disease and thirty-four
in amyotrophic lateral sclerosis. Id. at 23–24. The authors of the study concluded that “[p]regnant
women look set to miss out on the therapeutic advances expected from modern drug R&D in other fields
that will benefit from combinatorial chemistry, high throughput screening, pharmacogenomics,
bioinformatics, nanotechnology, the ‘-omic’ sciences, and biologics.” Id. at 25.
99. As of 2007, the only treatment for two of the three main pregnancy complications
(intrauterine growth restriction and pre-eclampsia) was childbirth. Fisk & Atun, supra note 98, at 26. In
the United States, there is no available approved treatment for the third (preterm labor), which is
managed with drugs and other interventions of questionable efficacy. Id. See also Hyagriv N. Simhan
& Steve N. Caritis, Prevention of Preterm Delivery, 357 NEW ENG. J. MED. 477, 479 (2009) (noting that
“the whole class of labor-inhibiting drugs is largely ineffective”).
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can be sold. 100 To secure approval, firms must demonstrate to the
FDA’s satisfaction that their products “are safe and effective for their
intended use.” 101 The FD&C Act requires that firms demonstrate safety
and efficacy through “adequate and well-controlled investigations.” 102
This provides firms with a powerful incentive to do the investigation
necessary to demonstrate to the satisfaction of the FDA that an
experimental drug is safe and effective for one intended use. 103 They
also have an incentive to do no more than necessary to secure approval,
because delays in approval can lessen, and certainly forestall, the period
of time during which they can sell their drug subject to patent-protected
market exclusivity. 104
The Drug Price Competition and Patent Term Restoration Act of 1984
(commonly known as Hatch-Waxman) strengthens the incentive
generated by the approval requirement by rewarding innovator firms
with the exclusive right to use the data they submit to the FDA for five
years. 105 For all practical purposes, this protects them from competition
during that time. 106 Having to redo the research necessary to establish
that a drug is safe and effective typically makes it cost-prohibitive for
competitors to seek regulatory approval to market drugs still in the
initial five-year data exclusivity period. 107
Like the patent regime, the incentive to develop information in order
to secure marketing approval from the FDA fails to generate the
information pregnant women need to make informed medication
choices. The FDA requires as a condition of approval that drugs be
tested to determine their potential to affect every stage of the
reproductive process. 108 These tests are primarily conducted on rats;
100. 21 U.S.C.A. § 331(d) (West 2010).
101. Eisenberg, supra note 86, at 730.
102. 21 U.S.C.A. § 355(d) (West 2010).
103. Eisenberg, supra note 86, at 730. See also Adriane Fugh-Berman & Douglas Melnick, OffLabel Promotion, On-Target Sales, 5 PLOS MED. 1432, 1433 (2008) (“In development, drugs may be
promising for several uses, and companies must choose one or two conditions on which to focus
research. Ease of approval is the most important factor in this decision.”).
104. Eisenberg, supra note 86, at 723 (explaining that firms are entitled to “patent term extensions
of up to five years to compensate for some of the time that the patent meter is ticking pending regulatory
approval of a new drug, so long as the total remaining patent life after extensions does not exceed
fourteen years from the date of approval”).
105. 21 U.S.C.A. § 355 (c)(3)(E)(ii) (West 2010).
106. Eisenberg, supra note 86, at 725, 730.
107. Once a drug’s data exclusivity period has expired, a competitor no longer has to file a new
drug application and show that its product is safe and effective. Instead, it can file an abbreviated new
drug application (ANDA) based on a showing that the drug is bioequivalent to the already-approved
drug. Id. at 727.
108. U.S. FOOD & DRUG ADMIN., DEPT. OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: M3(R2) NONCLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS
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tests to determine a drug’s potential to adversely affect embryo-fetal
development must usually be done on a second mammalian species as
well, preferably rabbits. 109 Even tests done on well-studied mammals
have a limited ability to predict human teratogenicity. 110 Drugassociated abnormalities can occur in animals that do not occur in
humans and vice versa. 111 For example, aspirin causes heart defects in
animals but not in humans, 112 whereas the well-known human teratogen
thalidomide caused no ill effects in animals. 113 The rubella vaccine does
not cross a pregnant monkey’s placenta, whereas in humans it crosses
the placenta and infects the fetus. 114 Further complicating the analysis,
drugs are tested in animals at doses which exceed the therapeutic dose in
humans, and certain animal species have different baseline rates of birth
defects. 115
The FDA does not require sponsors to test their experimental drugs in
pregnant women. In fact, under regulations and guidance promulgated
by both the Department of Health & Human Services (HHS) and the
FDA to protect the rights and interests of human research subjects,
pregnancy is grounds for exclusion from most pre-approval clinical
trials.
HHS’ human subject research regulations apply to research conducted
or supported by the agency, which encompasses the NIH among other
AUTHORIZATION FOR PHARMACEUTICALS 2 (2010), available at http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073246.pdf [hereinafter
2010 SAFETY STUDIES GUIDANCE].
109. U.S. FOOD & DRUG ADMIN., DEPT. OF HEALTH & HUMAN SERVS., GUIDANCE FOR
INDUSTRY: DETECTION OF TOXICITY TO REPRODUCTION FOR MEDICINAL PRODUCTS 12–13 (1994),
available
at
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm074950.pdf.
110. Wendy E. Wagner, Choosing Ignorance in the Manufacture of Toxic Products, 82 CORNELL
L. REV. 773, 774 (1997) (noting the tentative relationship between a product’s teratogenicity in animals
and its teratogenicity in humans).
111. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,841 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201).
112. Koren et al., supra note 33, at 1131.
113. Bonnie Steinbock, Ethical Issues Related to the Inclusion of Pregnant Women in Clinical
Trials (II), in 2 WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING WOMEN
IN CLINICAL STUDIES 23, 23 (Anna C. Mastroianni et al. eds., 1994).
114. THE NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAVIORAL
RES., U.S. DEP’T OF HEALTH, EDUCATION AND WELFARE, REPORT AND RECOMMENDATIONS:
RESEARCH ON THE FETUS 12 (1975) (“Preliminary testing of rubella vaccine in monkeys indicated that
the vaccine virus did not cross the placenta. In contrast, studies on women requesting therapeutic
abortion showed clearly that the vaccine virus did indeed cross the placenta and infect the fetus,
indicating the danger of administering the vaccine during pregnancy.”).
115. Content and Format of Labeling for Human Prescription Drugs and Biological Products;
Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg. 30,831, 30,841 (proposed May 29,
2008) (to be codified at 21 C.F.R. pt. 201).
AND MARKETING
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funders. 116 Beginning in 1991, when the HHS regulations were made
applicable to research conducted or supported by most other federal
agencies, they have been known as the “Common Rule.” 117 The
Common Rule references pregnant women several times, including them
on a list of “vulnerable” subjects along with children, prisoners,
handicapped or mentally disabled persons, and economically or
educationally disadvantaged persons. 118 The Rule provides that an
Institutional Review Board (IRB) that regularly reviews research
involving vulnerable subjects shall consider including on the IRB “one
or more individuals who are knowledgeable about and experienced in
working with these subjects.” 119 The Rule also provides that, in
fulfilling their duty to ensure that the selection of research subjects is
equitable, IRBs “should be particularly cognizant of the special
problems of research involving vulnerable populations,” and that
pregnant women and other subjects “likely to be vulnerable to coercion
or undue influence” should be provided with “additional safeguards” to
protect their rights and welfare. 120 Finally, the Common Rule specifies
that the informed consent form must include “[a] statement that the
particular treatment or procedure may involve risks . . . to the embryo or
fetus, if the subject is or may become pregnant[.]” 121
Subpart B of Title 45 of the Code of Federal Regulations—the
Common Rule is Subpart A—provides more specific guidance, setting
forth “ten criteria that must be met if pregnant women are to be included
in research protocols . . . .” 122 Notably, Subpart B requires that, where
scientifically appropriate, studies on pregnant animals and on nonpregnant women be conducted before pregnant women can be included
in research. 123 In addition, a fetus may not be placed at risk unless there
is a prospect for direct benefit to the woman or to the fetus, or unless the
risk is minimal and “the purpose of the research is the development of
important biomedical knowledge which cannot be obtained by any other

116. Carl H. Coleman, Rationalizing Risk Assessment in Human Subject Research, 46 ARIZ. L.
REV. 1, 5 (2004).
117. Id.
118. See 45 C.F.R. §§ 46.107(a), 46.111(a)(3), (b), 46.116(b)(1) (2010). As Carl Coleman notes,
the Common Rule does not define vulnerability and the examples it gives are diverse. Carl H. Coleman,
Vulnerability as a Regulatory Category in Human Subject Research, 37 J.L. MED. & ETHICS 12, 12
(2009). With regard to pregnant women, “it is not clear why any special issues related to capacity or
coercion would necessarily arise.” Id.
119. 45 C.F.R. § 46.107(a).
120. Id. § 46.111(a)(3), (b).
121. Id. § 46.116(b)(1).
122. Lyerly et al., supra note 14, at 18.
123. 45 C.F.R. § 46.204(a) (2010).
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means.” 124
Subpart B also imposes unique informed consent
requirements, providing that the woman’s consent to participate in
research is sufficient if there is the possibility of benefit to her, or to her
and the fetus, or if the risk is minimal and the research’s purpose is to
develop important biomedical knowledge that cannot otherwise be
obtained. 125 If there is a prospect of benefit to the fetus alone, however,
both the mother and father must give consent, with exceptions made if
the father “is unable to consent because of unavailability, incompetence,
or temporary incapacity or the pregnancy resulted from rape or
incest.” 126 Anne Drapkin Lyerly and her co-authors have opined that
Subpart B’s ten requirements lead researchers to “side-step the questions
and regulatory burden they represent by not including pregnant women”
in clinical trials. 127
The FDA has not adopted Subpart B. In the late 1970s, however, in
response to the diethylstilbestrol (DES) disaster, the agency
recommended that rigorous pre-conditions be met before fertile women
were included in the clinical trials it regulates, that is, those conducted in
support of an application for approval of a new drug. 128 The FDA’s
1977 guideline “General Considerations for the Clinical Evaluation of

124. Id. § 46.204(d). In the context of pediatric research, the requirement that studies hold out the
prospect of direct benefit has been interpreted broadly to include not just “[m]ost research on a drug to
cure or alleviate the discomfort of a subject with an underlying disorder or condition” but also placebocontrolled trials in which some number of enrollees receive an inert intervention. I. Glenn Cohen,
Therapeutic Orphans, Pediatric Victims? The Best Pharmaceuticals for Children Act and Existing
Human Subject Protections, 58 FOOD & DRUG L.J. 661, 694–96 (2003). See also Sanjiv B. Amin et al.,
Clinical Trials of Drugs Used Off-Label in Neonates: Ethical Issues and Alternative Study Designs, 15
ACCOUNTABILITY IN RES. 168, 171–75 (2008) (discussing the ethical issues arising in active controlled
and placebo controlled trials in neonates). Relying on evidence that even children who receive the
placebo in placebo-controlled trials benefit from their participation, including from increased care and
monitoring, the FDA has announced that placebo-controlled trials can be compatible with the direct
benefit requirement. Additional Safeguards for Children in Clinical Investigations of FDA-Regulated
Products, 66 Fed. Reg. 20,589, 20,593 (interim rule Apr. 24, 2001).
125. 45 C.F.R. § 46.204(d).
126. Id. § 46.204(e). Karen Rothenberg opines that:
It is incongruous that the paternal consent requirements in Subpart B have remained
in place while DHHS regulations on research involving children only require the
permission of one parent when such research poses either no greater than minimal risk or
the prospect of direct benefit to the child. . . . Subpart B and its “special” treatment of
pregnant women would become symbolic of the regulatory barriers to research that still
remain.
Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Women’s Health Care,
32 HOUS. L. REV. 1201, 1229 (1996).
127. Lyerly et al., supra note 14, at 18.
128. L. Elizabeth Bowles, Note, The Disfranchisement of Fertile Women in Clinical Trials: The
Legal Ramifications of and Solutions for Rectifying the Knowledge Gap, 45 VAND. L. REV. 877, 895–96
(1992).
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Drugs,” recommended that “[f]emales who are pregnant, or are at risk of
becoming pregnant, should be excluded” from Phase I clinical trials,
which include “the initial introduction of a drug into man.” 129 Phase I
trials can consist of drug dynamic and metabolic studies, toxicity and
pharmacologic effect studies on healthy research participants, and doseranging studies on patients to evaluate safety and possibly provide early
evidence of effectiveness. 130 They typically involve twenty to eighty
participants. 131 The guideline specified that all premenopausal women
who were “capable of becoming pregnant” were “women of
childbearing potential” and should be excluded, even if they were single,
used contraception, or were married to men who were vasectomized or
who used contraception. 132 Women in certain institutions, for example
prison, might not be “of childbearing potential,” but women in others,
for example mental institutions, would be. 133
Women of childbearing potential could be included in Phase II trials,
defined as “controlled trials designed to demonstrate effectiveness and
relative safety” including approximately one hundred to two hundred
participants, but only if earlier Phase II trials had already produced
“adequate information on efficacy and relative safety” and certain
recommended animal reproductive studies were complete; they could
not be included in Phase III trials, defined as expanded controlled and
uncontrolled trials designed to elicit additional evidence of safety and
efficacy, until all of the recommended animal reproductive studies were
complete. 134 The FDA only allowed for exceptions to the animal
reproductive studies requirement where the investigative drug could be
life-saving or life-prolonging, where the drug belonged to a class whose
teratogenic potential was known, or where the woman was
“institutionalized for a time period adequate to establish a non-pregnant
state.” 135 In these cases, the agency recommended that women be
pregnancy tested before taking the drug and that they be given advice
about appropriate contraceptives. 136
In the 1980s and early 1990s, attitudes towards clinical research
129. U.S. DEPT. OF HEALTH & HUMAN SERVS., FOOD & DRUG ADMIN., GENERAL
CONSIDERATIONS FOR THE CLINICAL EVALUATION OF DRUGS 7 (1977). Later in the document, the FDA
qualifies its advice, saying that women of childbearing potential should be excluded from Phase I
clinical trials “[i]n most cases,” id. at 7, and “in general,” id. at 10.
130. Id. at 6.
131. Id.
132. Id. at 10.
133. Id.
134. Id. at 6, 10.
135. Id. at 10.
136. Id. at 11.
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shifted. Women’s health advocates argued that the government and
clinical research establishment were harming women rather than helping
them by excluding them, pregnant or not, from research. 137 In 1986, the
National Institutes of Health (NIH) adopted a new policy encouraging
grant applicants to include women in their research plans. 138 In 1990, in
response to a Government Accounting Office (GAO) finding that the
policy adopted in 1986 had yet to be fully implemented, 139 the NIH
revised its approach. Grant applicants were required to include women
unless there was a “compelling justification” for exclusion. One
example of a compelling justification was that the research posed an
“unacceptable risk for women of childbearing age.” 140 Also in 1990, the
NIH for the first time required its own researchers to include women in
the absence of a “clear rationale” for exclusion. 141 Exclusion was
justified under the policy when the research to be conducted could
“expose the fetus to undue risks.” 142
In 1993, Congress stepped in, passing the National Institutes of
Health Revitalization Act, which required that women be included in
federally funded clinical studies unless their health or the purpose of the
research made their inclusion inappropriate; cost was not an acceptable
reason for exclusion. 143 The Act also required that federally funded
Phase III trials be designed to allow for the analysis of gender-linked
differences. 144 The NIH conformed its policy to the legislation,
promulgating new Guidelines on the Inclusion of Women and Minorities
as Subjects in Clinical Research in 1994. 145 For women of childbearing
potential, a presumption of inclusion in federally funded clinical trials
was now the law. The inclusion of pregnant women was still
conditioned on meeting Subpart B’s ten criteria, however.
In 1994, the Institute of Medicine (IOM) issued Women and Health
Research, a report written at the request of the NIH Office of Research
137. Christine Grady & Colleen Denny, Research Involving Women, in THE OXFORD TEXTBOOK
407, 409 (Ezekiel J. Emanuel et al. eds., 2008).
138. Id.
139. National Institutes of Health: Problems in Implementing Policy on Women in Study
Populations, Testimony Before the Subcomm. on Health and the Environment, Comm. on Energy and
Commerce, 101st Cong. 3–4 (1990) (statement of Mark Nadel, Associate Director, National and Public
Health Issues, Human Resource division), available at http://archive.gao.gov/d48t13/141859.pdf.
140. Karen H. Rothenberg, Gender Matters: Implications for Clinical Research and Women’s
Health Care, 32 HOUS. L. REV. 1201, 1231 (1996).
141. Id.
142. Id.
143. Id. at 142.
144. Grady & Denny, supra note 137, at 410.
145. NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research,
59 Fed. Reg. 11,146 (Mar. 9, 1994).
OF RESEARCH ETHICS
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on Women’s Health, which recommended that Subpart B be revised and
reissued to reflect a presumption of inclusion of pregnant women in
clinical trials. 146 The IOM Committee on the Ethical and Legal Issues
Relating to the Inclusion of Women in Clinical Studies concluded that:
It is the responsibility of investigators and IRBs to ensure that pregnant
women are provided with adequate information about the risks and
benefits to themselves, their pregnancies and their potential offspring.
Even when evidence concerning risks is unknown or ambiguous, the
decision about acceptability of risk to the pregnancy or to offspring
should be made by the woman as part of the informed consent process. 147

Most of the members of the Committee recommended in addition that
pregnant women not be excluded unless the IRB issued written findings
that “(1) there is no prospect of medical benefit to the pregnant woman,
and (2) a risk of significant harm to potential offspring is known or can
plausibly be inferred.” 148
Neither HHS nor the FDA adopted the IOM’s recommendations.
When the FDA revised its guidelines on the inclusion of women in
clinical trials, after a GAO audit requested by the Congressional Caucus
for Women’s Issues in 1992 found that women were underrepresented in
new drug research, the agency continued to recommend that pregnant
women be categorically excluded from clinical trials of new drugs. 149
The revised guidelines focus on ways to include women of childbearing
potential in trials without inadvertently exposing fetuses to potentially
toxic drugs. 150 They provide that “[i]n general, it is expected that
reproductive toxicity studies will be completed before there is largescale exposure of women of child-bearing potential, i.e., usually by the
end of phase 2 and before any expanded access program is
implemented.” 151 The FDA goes on to recommend that clinical
protocols include measures designed to minimize the possibility of fetal
exposure to investigational drugs, including use of the informed consent
process, pregnancy testing, and contraception, unless the purpose of a
trial is to study a drug’s effects during pregnancy. 152 Today, researchers
146. 1 COMM. ON ETHICAL & LEGAL ISSUES RELATING TO THE INCLUSION OF WOMEN IN
CLINICAL STUDIES, INST. OF MED., WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF
INCLUDING WOMEN IN CLINICAL STUDIES 194–95 (Anna C. Mastroianni et al. eds., 1994) [hereinafter
INST. OF MED.].
147. Id. at 195.
148. Id. at 198.
149. Rothenberg, supra note 126, at 1239.
150. Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of
Drugs, 58 Fed. Reg. 39,406, 39,409–11 (July 22, 1993).
151. Id. at 39,411.
152. Id.
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frequently ask women of childbearing age to agree to use birth control as
a condition of trial participation. 153 Sometimes, women are required to
use two methods of birth control, even though research shows that, at
least in some populations, this approach fails to reduce pregnancy
rates. 154
In a guidance document on nonclinical safety studies released in
January 2010, the FDA suggests that pregnant women need not always
be excluded from clinical trials. 155 In it, the agency states that pregnant
women may be included after “all female reproduction toxicity
studies . . . and the standard battery of genotoxicity tests” are completed
and “safety data from previous human exposure [has been]
evaluated.” 156
In sum, the FDA does not require that experimental drugs be tested in
pregnant women as a condition of approval. Rather, the agency has
actively discouraged such testing under most circumstances. The HHS
regulations are also restrictive. This is one reason why, although women
now constitute more than half of the population of research
participants, 157 “many researchers and institutional review boards
(IRBs) continue to regard pregnancy as a near-automatic cause for
exclusion . . . .” 158
This is not to suggest that experimental drugs should without
exception be tested in pregnant women as a condition of approval or that
if they were it would close the information gap. It may more often than
not prove impossible to conduct pre-approval testing in pregnant women
in a scientifically sound and ethical manner. If only a small number of
pregnant women are included in a given trial, the researchers may not be
able to draw statistically valid conclusions about the experimental drug’s
153. See, e.g., Stanford University Research Compliance Office, Stanford Consent Form Template
with
HIPAA
5,
available
at
http://humansubjects.stanford.edu/research/medical/
med_consent.html#forms (last visited Nov. 12, 2010) (suggesting that informed consent forms
incorporate the following language: “If you are a woman who is able to get pregnant, it is expected that
you will use an effective method of birth control to prevent exposing a fetus to a potentially dangerous
agent with unknown risk. If you are pregnant or currently breast feeding, you may not participate in this
study.”).
154. E-mail from Anne Drapkin Lyerly, Associate Professor of Obstetrics & Gynecology, Duke
Univ. Sch. of Med., to Kate Greenwood, Research Fellow and Lecturer in Law, Seton Hall Univ. Sch. of
Law (July 30, 2009, 11:49 EST) (on file with author).
155. 2010 SAFETY STUDIES GUIDANCE, supra note 108, at 18–19.
156. Id.
157. U. S. GEN. ACCOUNTING OFFICE, GAO-01-754, WOMEN’S HEALTH: WOMEN SUFFICIENTLY
REPRESENTED IN NEW DRUG TESTING, BUT FDA OVERSIGHT NEEDS IMPROVEMENT 3 (2001).
158. Lyerly et al., supra note 14, at 6. See also Diego F. Wyszynski, Pregnancy Exposure
Registries: Academic Opportunities and Industry Responsibility, 85 BIRTH DEFECTS RES. PART A:
CLINICAL & MOLECULAR TERATOLOGY 93, 93 (2009) (“[P]regnant women are actively excluded from
clinical trials[.]”).
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safety and efficacy during pregnancy. This could mean that the risks
taken by the women and their fetuses outweigh the benefits of including
them. Even clinical trials done exclusively on pregnant women are
frequently too small to allow for statistically sound conclusions about
rare birth defects. 159 Most human reproductive studies have fewer than
300 participants. 160 Given the baseline birth defect incidence of 3%, a
study of that size can rule out the possibility that a drug more than
doubles the risk of birth defects, but it will not be able to detect smaller
increases in risk. 161 Most women would consider smaller increases
significant. Cigarette smoking, for example, is associated with less than
a doubling of the risk of birth defects. 162 Moreover, while clinical trials
“focus on immediate adverse effects,” 163 pregnant women are equally
concerned about the long-term effects of in utero exposure to drugs on
their children’s growth and development. In the end, epidemiological
studies may be the only way to generate information about both rare
birth defects and long-term effects. However, such studies cannot be
done before a drug is approved and marketed.
C. Research Required for Permission to Make Marketing Claims About
a Prescription Drug
After a drug is approved, it is subject to a set of statutory and
regulatory provisions that incentivize its manufacturer to continue
developing information about its safety and efficacy. First, the FD&C
Act requires that on-label marketing claims be well-supported. An
advertisement violates the Act if it includes a representation or
suggestion, for example that one drug is better or safer than another
drug, that has not been demonstrated by either substantial evidence or
substantial clinical experience. 164 If a manufacturer wishes to make
certain claims it must be able to point to research that supports them; if
such research does not exist, the manufacturer has an incentive to
conduct it. Second, when the FDA grants permission to sell a
prescription drug, it does so for an indicated use or uses and subject to
159. Comments of Pharm. Res. and Mfrs. of Am. on Content and Format of Labeling for Human
Prescription Drugs and Biological Products; Requirements for Pregnancy and Lactation Labeling, 73
Fed. Reg. 30,831 (May 29, 2008).
160. Comments of Public Citizen on Content and Format of Labeling for Human Prescription
Drugs and Biological Products; Requirements for Pregnancy and Lactation Labeling, 73 Fed. Reg.
30,831 (May 29, 2008).
161. Id.
162. Id.
163. Lo & Friedman, supra note 71, at 465.
164. 21 C.F.R. § 202.1(e)(6)(i) (2010).
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the terms and conditions specified in the approved label. 165 While
physicians are free to prescribe the drug for any purpose or in any
manner they deem appropriate, the FD&C Act prohibits the
manufacturer from promoting the drug except in accord with its agencyapproved label. 166 This ban on off-label promotion creates an incentive
for manufacturers to conduct the research needed to support a
supplemental new drug application to move off-label doses, indications,
methods of administration, or patient populations on-label. Finally,
Hatch-Waxman rewards manufacturers who submit successful
supplemental new drug applications with a supplemental period of data
exclusivity.
Under Hatch-Waxman, if a company submits a supplemental new
drug application supported by “new clinical investigations” and the FDA
approves the application, the company is rewarded with three additional
years of data exclusivity. 167 If the initial five-year data exclusivity
period has expired, competitors are not barred from relying on the data
submitted in support of the original indication in seeking approval to
manufacture a generic version of the drug. 168 While a generic
manufacturer cannot promote the drug for the use that is protected by the
three additional years of data exclusivity, doctors are free to prescribe
the generic version for either the original or the newly approved use.
This weakens the incentive Hatch-Waxman gives to innovator firms to
conduct the research necessary to support a supplemental new drug
application.
The ban on off-label promotion provides firms with an additional
push “to go through the strict FDA preclinical and clinical trial process
to get off-label uses on-label.” 169 If a company wishes to promote a
drug for a previously unapproved use, it must conduct the clinical
investigations necessary to establish the drug’s safety and efficacy for
that use and then submit a supplemental new drug application to the
FDA. Supplemental new drug applications are required any time a
company wishes to make a “major” change to a drug’s label. 170 This
could include an additional indication as well as a change in dose,

165. Rebecca Dresser & Joel Frader, Off-Label Prescribing: A Call for Heightened Professional
and Government Oversight, 37 J.L. MED. & ETHICS 476, 477 (2009).
166. Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 55–56 (D.D.C. 1998), amended by 36 F.
Supp. 2d 16 (D.D.C. 1999), vacated in part by Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir.
2000).
167. 21 U.S.C.A. § 355(c)(3)(E)(iii) (West 2010).
168. Eisenberg, supra note 86, at 729.
169. Friedman, 13 F. Supp. 2d at 70–71 (D.D.C. 1998).
170. 21 C.F.R. § 314.70(b) (2010).
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method of administration, or patient population. 171
The FDA frequently disavows jurisdiction over the practice of
medicine. It has noted that “unapproved ‘or more precisely, unlabeled’
uses may be appropriate and rational in certain circumstances, and may,
in fact reflect approaches to drug therapy that have been extensively
reported in medical literature.” 172 In the device context, the FD&C Act
states that “nothing in this chapter shall be construed to limit or interfere
with the authority of a health care practitioner to prescribe or administer
any legally marketed device to a patient for any condition or disease
within a legitimate health care practitioner-patient relationship,” and the
Supreme Court has held that off-label use “is an accepted and necessary
corollary of the FDA’s mission to regulate in this area without directly
interfering with the practice of medicine.” 173
While off-label use is permitted, off-label promotion is not. 174 First,
the FD&C Act bans the sale of unapproved “new drug[s,]” 175 and when
an approved drug is marketed for an unapproved use, the FDA’s position
is that the drug becomes “an unapproved new drug with respect to that
use.” 176 The agency reasons that the Act’s definition of “new drug”
includes any drug that the FDA has not determined to be “safe and
effective for use under the conditions prescribed, recommended, or
suggested in [its] labeling.” 177 Labeling, in turn, is defined to include
“all labels and other written, printed, or graphic matters” on the drug
itself, on the drug’s “containers or wrappers,” or that accompany the
drug. 178 The Supreme Court has held that written matters “accompany”
a drug when they “supplement[] or explain[] it, in the manner that a
committee report of the Congress accompanies a bill. No physical
attachment one to the other is necessary. It is the textual relationship
171. Ass’n of Am. Physicians & Surgeons, Inc. v. FDA, 226 F. Supp. 2d 204, 206 (D.D.C. 2002).
172. Citizen Petition Regarding the Food and Drug Administration’s Policy on Promotion of
Unapproved Uses of Approved Drugs and Devices; Request for Comments, 59 Fed. Reg. 59,820, 59,821
(Nov. 18, 1994).
173. Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 350 (2001) (citing 21 U.S.C. § 396
(1994 & Supp. V)).
174. The FDA does allow certain company communications about off-label uses. For example,
companies can distribute, among other things, peer-reviewed medical journal articles that discuss such
uses. See U.S. FOOD & DRUG ADMIN., DEPT. OF HEALTH & HUMAN SERVS., GUIDANCE FOR INDUSTRY
- GOOD REPRINT PRACTICES FOR THE DISTRIBUTION OF MEDICAL JOURNAL ARTICLES AND MEDICAL OR
SCIENTIFIC REFERENCE PUBLICATIONS ON UNAPPROVED NEW USES OF APPROVED DRUGS AND
APPROVED OR CLEARED MEDICAL DEVICES (2009), available at http://www.fda.gov/
RegulatoryInformation/Guidances/ucm125126.htm.
175. 21 U.S.C.A. §§ 331(d), 355(a) (West 2010).
176. U.S. FOOD & DRUG ADMIN., supra note 174.
177. 21 U.S.C.A. § 321(p) (West 2010).
178. § 321(m). But cf. § 321(k) (defining “label” more narrowly, to include “a display of written,
printed, or graphic matter upon the immediate container of any article”).
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that is significant.” 179 Whenever a company makes promotional claims
in writing about an unapproved use of a drug, then, the drug becomes a
“new drug” for purposes of that use, which makes it illegal to sell the
drug for that use under the FD&C Act.
Off-label promotion is prohibited for a second reason. When a
company promotes its drug for an off-label use the drug becomes
“misbranded” and therefore banned for sale under the Act. 180 The Act
requires that labeling contain “adequate directions” for “intended”
uses. 181 FDA regulations require that a prescription drug’s labeling
include
adequate information for its use, including indications, effects, dosages,
routes, methods, and frequency and duration of administration, and any
relevant hazards, contraindications, side effects, and precautions under
which practitioners licensed by law to administer the drug can use the
drug safely and for the purposes for which it is intended, including all
purposes for which it is advertised or represented[.] 182

Intent is defined objectively, with reference to, for example, “labeling
claims, advertising matter, or oral or written statements by such persons
or their representatives.” 183 A company’s promotional claims about an
unapproved use demonstrate that the use is “intended;” because the label
lacks adequate directions for the use, the drug is misbranded and banned
for sale.
A number of factors are considered by companies when deciding
whether to file a supplemental new drug application. A key factor is the
projected increase in sales obtaining such approval would generate.
Sales could increase for a variety of reasons. The fact of the FDA’s
approval could have a positive effect on perceptions of the drug, or the
addition of new information to the label could bring it to the attention of
new health care providers and patients. New indications can have halo
effects. If a painkiller is approved to treat one particularly painful
condition, physicians and patients might believe that it is efficacious for
other such conditions. Most observers agree that the central advantage
to adding a new use to the label is that it allows the manufacturer to
promote the drug for that use. 184
179. Kordel v. United States, 335 U.S. 345, 350 (1948).
180. U.S. FOOD & DRUG ADMIN., supra note 174 (citing 21 U.S.C. § 352(f); 21 C.F.R.
§ 201.100(c)(1)).
181. 21 U.S.C.A. § 352(f)(1) (West 2010).
182. 21 C.F.R. § 201.100(c)(1) (2010).
183. Id. § 201.128.
184. See, e.g., Wash. Legal Found. v. Friedman, 13 F. Supp. 2d 51, 70 (D.D.C. 1998) (holding
that “defendants have proved to this court’s satisfaction that dissemination of scientific information on
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In addition to direct-to-consumer advertising, promotion includes
physician detailing, both the traditional visits by sales representatives to
doctors’ offices and newer online approaches. 185 Companies also
promote their products by engaging physicians to give promotional talks
to their fellow doctors 186 and by running advertisements targeting
physicians in medical journals, on the internet, and elsewhere. 187
Promotion to health insurance companies, managed care organizations,
and pharmaceutical benefit management firms is also prevalent. 188
The authors of a recently published meta-analysis of fifty-eight
studies concluded that “promotional expenditures have a significant and
positive effect on sales in pharmaceutical markets,” but that “the
elasticities of promotional expenditures are modest in size[.]” 189
Physician detailing is the most effective form of promotion in most
markets, followed by direct-to-physician advertising. 190 Demonstrated
effectiveness aside, the amounts pharmaceutical firms spend on
promotion suggest that they have concluded it is effective, which in turn
suggests that they would view permission to promote positively. IMS
Health, self-described as “the world’s leading provider of market

off-label uses is an effective means of influencing physicians to prescribe a drug for a given
condition. . . . Consequently, the dissemination of information demonstrating that a drug is effective has
a positive effect upon sales of the drug.” (citations omitted)), amended by 36 F. Supp. 2d 16 (D.D.C.
1999), vacated in part by Wash. Legal Found. v. Henney, 202 F.3d 331 (D.C. Cir. 2000); Catherine
Larkin, Lilly Wins Backing to Use Antidepressant Cymbalta for Back, Arthritis Pain, BLOOMBERG, Nov.
4,
2010,
http://www.bloomberg.com/news/2010-11-04/lilly-wins-backing-to-use-antidepressantcymbalta-for-back-arthritis-pain.html (citing an analyst’s estimate that the approval of a supplemental
new drug application for the antidepressant Cymbalta will result in a $500 million increase in annual
sales).
185. Marc Iskowitz, Pfizer Nearly Doubles Amount Spent on E-Detailing, MMM-ONLINE, Jan.
19, 2010, http://www.mmm-online.com/pfizer-nearly-doubles-amount-spent-on-e-detailing/article/
161727/.
186. See PHARM. RES. & MFRS. OF AM., CODE ON INTERACTIONS WITH HEALTHCARE
PROFESSIONALS 9–10 (2008) (setting forth ethical guidelines for company-run “Speaker Programs and
Speaker Training Meetings”).
187. See Puneet Manchanda & Elisabeth Honka, The Effects and Role of Direct-to-Physician
Marketing in the Pharmaceutical Industry: An Integrative Review, 5 YALE J. HEALTH POL’Y L. &
ETHICS 785, 785–86 (2005) (“The marketing efforts directed at physicians comprise personal selling
through sales representatives (detailing); sampling (provision of drugs at no cost); physician meetings
and events; and advertisements in medical journals.” (citations omitted)); Running a Hospital,
http://runningahospital.blogspot.com/2009/05/3-1-1-0.html (May 26, 2009, 06:37 PM) (questioning the
efficacy of an advertisement for an atrial fibrillation catheter that appeared on plastic bags handed out by
airport security; commenters noted that the distribution of the bags coincided with a meeting of the
Heart Rhythm Society).
188. John E. Calfee et al., Direct-to-Consumer Advertising and the Demand for CholesterolReducing Drugs, 45 J.L. & ECON. 673, 678 (2002).
189. Sara T.M. Kremer et al., Generalizations on the Effectiveness of Pharmaceutical
Promotional Expenditures, 25 INT’L J. RES. MKTG. 234, 244 (2008).
190. Id.
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intelligence to the pharmaceutical and healthcare industries,” 191
estimates that in 2009 companies spent $4.34 billion on direct-toconsumer advertising, $6.29 billion on sales representative detailing, and
$315 million on medical journal advertising, for a total United States
promotional spend of $ 1.09 billion. 192
In addition to whether a supplemental new drug application will lead
to increased sales, companies must also consider whether, as a scientific
matter, they will be able to support the new indication or other additions
to the label they hope to make. They must also consider the cost of
mounting the necessary clinical trials and the risk that the trial results
might be negative and cause their consumer base to shrink rather than
expand. 193 There is no expectation or requirement that companies factor
public health priorities into their calculus.
Like the initial approval requirement, both the requirement that
promotional claims be well-supported and the supplemental approval
requirement are of limited benefit to pregnant women. First, the fact
that the additional period of exclusivity is only granted to manufacturers
if they present the results of a “new clinical investigation” limits the
value of the incentive for pregnant women. Epidemiological studies
may be as valuable as or more valuable than clinical trials as a route to
expanding our knowledge of maternal–fetal pharmacology, particularly
with regard to safety information. More fundamentally, for most drugs,
permission to freely promote them to a small, transient patient
population like pregnant women is unlikely to be enticing to companies.
Analogously, prior to the enactment of legislation establishing special
incentives for pediatric labeling changes, companies declined to test
their products on children and were content to let the labels reflect the
lack of pediatric safety or efficacy information. 194 Finally, a pregnancy
section that reflects the fact that a drug is unstudied in pregnant women
is less of a handicap than it might be because most drugs are similarly
unstudied. For example, in a case brought against GlaxoSmithKline
191. IMS, IMS Facts at a Glance, http://www.imshealth.com/portal/site/imshealth/menuitem
(follow “About Us . . . more” hyperlink; then follow “Facts-At-a-Glance” hyperlink) (last visited Feb.
25, 2010).
192. IMS, Total U.S. Promotional Spend by Type, 2009, http://www.imshealth.com/
deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/PromoUpdate2009.pdf (last visited
Nov. 8, 2010).
193. See Leslie Kushner, Note, Incentivizing Postmarketing Pharmaceutical Product Safety
Testing with Extension of Exclusivity Periods, 19 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 519,
537–39 (2009) (discussing impact of safety findings on sales of the anemia drug Aranesp and the
multiple sclerosis drug Tysabri).
194. Lauren Hammer Breslow, Note, The Best Pharmaceuticals for Children Act of 2002: The
Rise of the Voluntary Incentive Structure and Congressional Refusal to Require Pediatric Testing, 40
HARV. J. ON LEGIS. 133, 152–53 (2002).
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alleging that its anti-depressant Paxil caused birth defects, witnesses for
the plaintiff testified at trial that GSK sales representatives exhorted
physicians to prescribe Paxil on the grounds that (1) at that time, it was
in category C 195 and (2) no drug in its class had been shown to be safer
in pregnancy. 196
D. Research Required by Products Liability Law
Companies’ potential exposure to tort liability also influences their
decisions to conduct clinical trials or otherwise develop information
about their drugs when used during pregnancy. First, companies have
an incentive to study their drugs to the extent that early detection of
safety issues reduces the number of injuries caused by a drug and,
concomitantly, reduces a company’s exposure to damage awards. Many
argue, albeit with the benefit of hindsight, that the manufacturers of the
well-known teratogens DES and thalidomide increased their liability
exposure by inadequately testing their drugs. Second, the tort system
incentivizes companies to study their drugs because they can be liable
for failure to warn of risks for which they did not test. The Paxil case,
Kilker v. SmithKline Beecham, is an example of this. In October 2009,
the jury found that GSK was negligent, albeit not grossly so, for failing
to warn of an association between Paxil and certain cardiac birth
defects. 197 The jury awarded the plaintiff $2.5 million 198 and GSK
subsequently agreed to pay more than $1 billion to settle over 800
additional cases. 199 On the other hand, the tort system negatively
incentivizes companies, because they are exposed to liability for harms
incurred by research participants and because they are often sued when
adverse research results are announced regardless of whether they acted
responsibly. GSK may view the Paxil case as an example of the latter

195. Transcript of Testimony of David Healy at 20, Kilker v. SmithKline Beecham Corp. (Pa. Ct.
Com. Pl. Sept. 16, 2009 Morning Session) (No. 1813) (attorney for the plaintiff Sean Patrick Tracey
representing to the court that “Dr. Ruppersberger has testified that the GSK sales reps came to his office
and pushed him to prescribe this drug to women of childbearing age because it was a Category C”).
196. Transcript of Testimony of Suzanne Parisian at 31–32, Kilker v. SmithKline Beecham Corp.
(Pa. Ct. Com. Pl. Sept. 18, 2009 Afternoon Session) (No. 1813) (reviewing a memorandum for sales
representatives and affirming that “[i]t says study, reinforce what you have already been telling
physicians. No SSRI has been shown to have superior safety versus Paxil for use during pregnancy[.]”).
197. Jef Feeley & Sophia Pearson, Glaxo Ordered to Pay $2.5 Million for Paxil Defects
Oct.
13,
2009,
http://www.bloomberg.com/apps/
(Update4),
BLOOMBERG,
news?pid=20601103&sid=apENrx2KUBcY.
198. Id.
199. Jef Feeley & Trista Kelley, Glaxo Said to Have Paid $1 Billion Over Paxil Suits,
BLOOMBERG, July 20, 2010, http://www.bloomberg.com/news/2010-07-20/glaxo-said-to-have-paid-1billion-to-resolve-paxil-birth-defect-lawsuits.html.
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phenomenon. In this subpart, I elaborate on the above incentives and
conclude that it is impossible to precisely calibrate and weigh them
against one another to determine whether the tort system, on balance,
incentivizes or disincentivizes research. I then discuss reasons why
research studying the effects of drugs on pregnant women and fetuses
might be especially susceptible to a liability barrier.
To the extent that research reveals a drug’s potential to cause harm
before the drug causes actual harm, the company that conducted the
research will be rewarded for doing so in the form of reduced exposure
to liability. In a commissioned paper accompanying the IOM’s 1994
report Women and Health Research, Ellen Wright Clayton predicted that
pharmaceutical manufacturers’ “potential for liability is much greater if
efforts are not made to detect fetotoxic effects.” 200 She argued that if a
drug with unknown but knowable fetotoxic effects were to enter the
marketplace and be widely used before those effects were discovered,
many children would be harmed and their lawyers would argue that the
manufacturer had a duty to discover the drug’s ill effects. 201 Clayton
contrasts this scenario with a manufacturer who studies its drug prior to
marketing and discovers its fetotoxic effects at an early stage. She notes
that “the risk of incurring liability during the early stages of drug
investigation is actually quite small” and that a manufacturer who is
aware of a drug’s fetotoxicity can “transfer the risk of liability to the
health care provider under the learned intermediary doctrine.” 202
An argument can be made that the three drugs most often cited as
evidence of a liability barrier to researching the safety and efficacy of
drugs when used during pregnancy—thalidomide, DES, and
Bendectin—in fact support Clayton’s position. In all three cases, the
manufacturer or manufacturers’ liability would have been reduced had
they researched their products’ teratogenecity before marketing them. 203
Bendectin is an especially interesting case study. The drug was
prescribed to more than thirty-three million pregnant women to treat
pregnancy-induced nausea and vomiting between 1956, when it was
introduced, and 1983, when its manufacturer, Merrell Dow, withdrew it
200. Ellen Wright Clayton, Liability Exposure When Offspring Are Injured Because of Their
Parents’ Participation in Clinical Trials, in 2 WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL
ISSUES OF INCLUDING WOMEN IN CLINICAL STUDIES 108 (Anna C. Mastroianni et al. eds., 1994).
201. Id. at 109.
202. Id. at 103, 109. Adopted by almost all jurisdictions, the learned intermediary doctrine
provides that manufacturers are not obliged to warn patients directly; giving an adequate warning to the
physicians who prescribe the drug suffices. See Margaret Gilhooley, Learned Intermediaries,
Prescription Drugs, and Patient Information, 30 ST. LOUIS U. L.J. 633, 634 (1985).
203. Edward J. Saunders & Jeanne A. Saunders, Drug Therapy in Pregnancy: The Lessons of
Diethylstilbestrol, Thalidomide, and Bendectin, 11 HEALTH CARE FOR WOMEN INT’L 423, 423 (1990).
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from the United States market citing the large and increasing number of
lawsuits alleging that the drug caused birth defects. 204 At its peak,
Bendectin was prescribed to up to 40% of pregnant women. 205
Despite the fact that Bendectin was indicated for use during
pregnancy and was in fact used by millions of pregnant women, Merrell
Dow did not test its ingredients for reproductive toxicity prior to
marketing. 206 The FDA did not require such tests at the time, and each
of the drug’s three ingredients was prescribed singly without recorded
adverse effects. 207 Merrell Dow’s decision not to test Bendectin did not
result in fetal harm; multiple large, high-quality epidemiological studies
have found no causal relationship between the drug and birth defects. 208
Wendy Wagner contends that the reason some Bendectin plaintiffs
nevertheless prevailed was at least in part because of Merrell Dow’s
failure to engage in information development, namely its failure to test
Bendectin’s long-term safety and its prior failure to test adequately
MER/29 and thalidomide, products which caused severe harm. 209 The
plaintiffs’ evidence of these failures was “largely unrebutted.” 210 Joseph
Sanders’ review of multiple trial transcripts showed that the Bendectin
plaintiffs commingled the relatively strong evidence that Merrell Dow’s
testing and marketing of the drug was negligent with the relatively weak
evidence that the drug caused harm. 211 A survey of several jurors in a
case in which a Bendectin plaintiff won large compensatory and punitive
damage awards revealed that the plaintiffs’ strategy was effective; the
jurors spent more time on the evidence of Merrell Dow’s scientific
misconduct than on any other evidence. 212
The tort system also rewards companies for studying their drugs
because by doing so they reduce the chance that they will be found
liable for failure to warn of risks for which they failed to test. Failureto-test prescription drug claims are typically brought under the rubric of
failure to warn of an unknown but knowable risk. The Restatement
(Third) of Torts provides as follows:
A prescription drug or medical device is not reasonably safe due to
204. Jane E. Brody, Shadow of Doubt Wipes Out Bendectin, N.Y. TIMES, June 19, 1983, at E7.
205. Koren et al., supra note 33, at 1129.
206. Joseph Sanders, The Bendectin Litigation: A Case Study in the Life Cycle of Mass Torts, 43
HASTINGS L.J. 301, 321 (1992).
207. Id. at 317, 321.
208. Joseph Sanders, From Science to Evidence: The Testimony on Causation in the Bendectin
Cases, 46 STAN. L. REV. 1, 7 (1993).
209. Wagner, supra note 110, at 829–30.
210. Id.
211. Id.
212. Id.
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inadequate instructions or warnings if reasonable instructions or warnings
regarding foreseeable risks of harm are not provided to: (1) prescribing
and other health-care providers who are in a position to reduce the risks
of harm in accordance with the instructions or warnings; or (2) the patient
when the manufacturer knows or has reason to know that health-care
providers will not be in a position to reduce the risks of harm in
accordance with the instructions or warnings. 213

The Restatement provides that drug “manufacturers have the
responsibility to perform reasonable testing prior to marketing a product
and to discover risks and risk-avoidance measures that such testing
would reveal.” 214 After marketing a product, companies have a
continuous duty “to keep abreast of the current state of knowledge . . . as
gained through research, adverse reaction reports, scientific literature,
and other available methods.” 215
It is not clear from the case law to what extent companies must
engage in independent testing once a product is on the market. 216 In the
Paxil case, the plaintiff successfully argued that GSK was negligent
because it (1) failed to conduct additional animal testing, beyond what
the FDA required, to determine why Paxil had the effects that it did on
the animals studied, and (2) failed to warn doctors of Paxil’s risks once
the company began receiving adverse event reports of birth defects. 217
In Horne v. Novartis Pharmaceuticals, by contrast, the District Court for
the Western District of North Carolina granted the defendant
manufacturer’s motion to dismiss the plaintiff’s failure to warn claim,
finding that the plaintiff’s claim was preempted in part because she
failed to allege that:
at the time of her pregnancy, the Defendant possessed any studies
revealing birth defects associated with the first trimester use of Lotensin
HCT® in particular or ACE inhibitors in general. Nor has the Plaintiff

213. RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 6(d) (1998). Many medications
are used “off-label” in pregnant women, for example nifedipine, an anti-hypertensive drug, and
terbutaline, an anti-asthmatic drug, both of which are prescribed to arrest pre-term labor. Courts have
held that manufacturers are liable for failure to warn of known risks attendant to off-label uses if the
uses are reasonably foreseeable. See Knipe v. Smithkline Beecham, 583 F. Supp. 2d 602, 629 (E.D. Pa.
2008) (citing cases).
214. RESTATEMENT (THIRD) OF TORTS: PRODUCTS LIABILITY § 6 cmt. g (1998). See also id. § 10
cmt. c (charging sellers with “knowledge of what reasonable testing would reveal” and noting that
“courts traditionally impose a continuing duty of reasonable care to test and monitor after sale to
discover product-related risks.”).
215. Lindsay v. Ortho Pharm. Corp., 637 F.2d 87, 91 (2d Cir. 1980).
216. Lars Noah, This is Your Products Liability Restatement on Drugs, 74 BROOK. L. REV. 839,
907 (2009).
217. Transcript of Opening Statement of Sean Patrick Tracey at 31–32, 49–50, Kilker v.
SmithKline Beecham Corp. (Pa. Ct. Com. Pl. Sept. 15, 2009) (No. 1813).
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alleged that the Defendant had any “reasonable evidence” of such a
causal association at the time of her pregnancy which would have
required the revision of the labeling[.] 218

Clearly, products liability law gives companies a strong incentive to stay
abreast of third-party research, and to make immediate changes to
product warnings as science advances. Their incentive to advance the
science themselves is weaker. 219 As the Paxil verdict shows, however,
there is a real risk that a jury will find a company’s choice not to study
its product unreasonable.
Many believe that any reduction in exposure to failure-to-warn
liability from information development is outweighed by its exposureincreasing effects and that there is in fact a liability barrier that is
responsible for the slow pace of information development. 220 For one,
drug companies and others involved in clinical research have been sued
when participants in clinical trials sustained injury. 221 In cases in which
218. Horne v. Novartis Pharms. Corp., 541 F. Supp. 2d 768, 782–83 (W.D.N.C. 2008) (internal
citation omitted).
219. George Conk and others have argued that, whatever its precise contours, the tort law duty to
test approved products for safety issues is inadequate. See Lars Noah, Platitudes about “Product
Stewardship” in Torts: Continuing Drug Research and Education, 15 MICH. TELECOMM. & TECH. L.
REV. 359, 360 (2009) (citing George W. Conk, Punctuated Equilibrium: Why § 402A Flourished and
the Products Liability Restatement Languished, 26 REV. LITIG. 799, 856–62, 878–80 (2007); Margaret
A. Berger & Aaron D. Twerski, Uncertainty and Informed Choice: Unmasking Daubert, 104 MICH. L.
REV. 257 (2005)). Conk believes that companies have or should have a duty of “product stewardship”
which flows “from the manufacturer’s design experience and from the marketer’s observation of its
product’s performance in the field.” George W. Conk, The True Test: Alternative Safer Designs for
Drugs and Medical Devices in a Patent-Constrained Market, 49 UCLA L. REV. 737, 749 (2002). Lars
Noah has argued in opposition to proposals like these that a “duty to investigate all foreseeable uses to
which health care professionals might put an approved drug would be entirely unmanageable, and it
would threaten to deprive intended users of a valuable product.” Noah, supra note 216, at 907.
220. See, e.g., PETER W. HUBER, LIABILITY: THE LEGAL REVOLUTION AND ITS CONSEQUENCES
155 (1988) (quoting statement of pharmaceutical company president that no one in his or her “right
mind” would develop products for pregnant women because of the liability exposure); Fisk & Atun,
supra note 98, at 26 (ascribing the failure to “test (let alone develop) drugs in pregnancy” to “risk
aversion to the possibility of teratogenicity” which “is exacerbated by high lifelong settlement costs for
a baby damaged in utero” and “by a jury-determined tort process, which favours punitive damages”);
Vanessa Merton, Impact of Current Federal Regulations on the Inclusion of Female Subjects in Clinical
Studies, in 2 WOMEN AND HEALTH RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING WOMEN IN
CLINICAL STUDIES 65, 76 n.2 (Anna C. Mastroianni et al. eds., 1994) (predicting that, absent regulatory
compulsion, liability concerns would remain “formidable obstacles to the participation of women as
subjects in biomedical research”); Comment of DV Jr. to Ed Silverman, Nothing in the Oven for
Pregnancy Complications, PHARMALOT, June 4, 2008, http://www.pharmalot.com/2008/06/nothing-inthe-oven-for-pregnancy-complications (“While acknowledging the problem, I have to say a drug
company would be C-R-A-Z-Y to investigate a product in pregnant women in today’s litigation-friendly
environment.”); Comment of Ol Cranky to Ed Silverman, Nothing in the Oven for Pregnancy
Complications, PHARMALOT, June 4, 2008, http://www.pharmalot.com/2008/06/nothing-in-the-ovenfor-pregnancy-complications (“The risk would have been way too huge for most companies to consider
years ago – now it would be absolute suicide.”).
221. Randi Zlotnik Shaul et al., Legal Liabilities in Research: Early Lessons from North America,
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the way the research was conducted caused harm, trial participants may
have a negligence claim against the research sponsor to the extent that
the sponsor failed to fulfill its duties to ensure that the investigators were
well-qualified and to closely monitor their work. 222 Where it was the
research intervention itself that caused the harm, plaintiffs have sued
research sponsors on a variety of theories. 223 Battery claims may be
brought by research participants who allege that they did not know or
did not consent to the research; negligence claims may be brought by
participants who knew about the research and consented to participate in
it, but who allege that they were not told everything they needed to
know to make an informed decision. 224 While a plaintiff participant’s
informed consent generally protects defendants from such allegations,
when the participant is a pregnant woman and the injury is to her child,
there is an added wrinkle because a fetus, of course, cannot give
consent. That said, a child whose mother consented to participate in a
clinical trial while pregnant probably could not successfully argue that
he or she would not have given his or her consent. 225
Although research-related litigation is more common than it once
was, clinical trial participants, pregnant or not, bring relatively few
liability claims and the body of case law remains small. 226 Only four
cases involving fetal harm brought on by participation in clinical trials
have led to reported decisions. 227 In all four, the plaintiffs claimed that
BMC MED. ETHICS 6:4, June 2005 http://www.biomedcentral.com/content/pdf/1472-6939-6-4.pdf.
222. 21 C.F.R. § 312.50 (2010).
223. See, e.g., Craft v. Vanderbilt Univ., 18 F.Supp.2d 786, 789 (M.D. Tenn. 1998) (Plaintiffs,
previously pregnant women and the children they were carrying, who were non-consenting subjects of
experiments involving radioactive iron, sued under multiple federal and state law theories including
battery, negligence, and medical malpractice.).
224. For example, in Berman v. The Fred Hutchinson Cancer Research Ctr., No. C01-0727L
(W.D. Wa. Aug. 8, 2002), the court found that the plaintiff’s consent was invalid because she was
promised, falsely, that she could receive a chemotherapy drug intravenously if she could not tolerate oral
administration. Courts have also found that the failure to disclose certain conflicts of interest can
invalidate consent. See, e.g., Darke v. Estate of Isner, 17 Mass. L. Rptr. 689 (Mass. Super. Ct. 2004)
(holding that a doctor could be subject to medical malpractice liability under Massachusetts law for
failing to disclose to his patient that he had a financial interest in the clinical trial that he recommended
to his patient).
225. Anna C. Mastroianni, HIV, Women, and Access to Clinical Trials: Tort Liability and Lessons
from DES, 5 DUKE J. GENDER L. & POL’Y 167, 179–80 (1998).
226. See Noah, supra note 216, at 839 n.293; Jill Wadlund, Heading off a Clinical Trial Liability
Lawsuit, 12 APPLIED CLINICAL TRIALS 50, 50 (2003).
227. An unreported case of note is Crayton v. UT Med. Group Inc., No. CT-007219-04 (Tenn. Cir.
Ct. Dec. 28, 2004), which involved a pregnant woman who participated in a clinical trial evaluating the
safety and efficacy of two drugs used to prevent maternal–fetal transmission of the HIV virus. Andrew
M. Ballard, Wrongful Death Lawsuit Filed in Tennessee Over Clinical Trial Using AIDS Drug
RES.
L.
&
POL’Y
REP.,
Jan.
2005,
available
at
Nevirapine,
MED.
http://healthcenter.bna.com/pic2/hc.nsf/id/BNAP-68LRCB?OpenDocument (reporting on Crayton).
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they did not give their informed consent and in fact did not know that
they were part of an experiment. 228 These cases therefore provide only
limited guidance on the extent of liability for fetal harm when a pregnant
woman has consented to participate. It is clear from non-researchrelated case law that a pregnant woman can consent to medical treatment
for herself and for her fetus. 229 The informed consent provisions of the
regulations governing the inclusion of pregnant women in clinical trials,
which provide that consent can be given on behalf of a fetus by
expectant mothers and fathers, support the conclusion that consent is as
protective in the research context. 230 Notably, case law authorizes
parents to consent to their born children’s participation in “therapeutic
research that represents a valid alternative and may be the functional
equivalent of treatment[.]” 231 While at least one court has limited
parents’ authority to consent to their children’s participation in nontherapeutic research that poses more than a minimal risk, 232 the federal

The woman’s baby was delivered by cesarean section after the woman developed severe side effects. Id.
The woman died two days later. Id. The plaintiffs’ claimed that the two defendant pharmaceutical
companies “failed to adequately warn consumers of the potential adverse side effects associated with
their products and were negligent in the design, manufacture, testing, advertising, warning, marketing,
and sale of the drugs.” Id.
228. See Diaz v. Hillsborough County Hosp. Auth., No. 8:90-CV-120-T-25B, 2000 U.S. Dist.
LEXIS 14061 (M.D. Fla. Aug. 7, 2000); Craft, 18 F. Supp. 2d 786; Wetherill v. Univ. of Chicago, 570
F. Supp. 1124 (N.D. Ill. 1983); Mink v. Univ. of Chicago, 460 F. Supp. 713 (N.D. Ill. 1978). The lead
plaintiff in the Diaz case, Flora Diaz, participated in a study of drugs used to accelerate fetal lung
development which randomized pregnant women between standard treatment with corticosteroids and
an experimental combination of corticosteroids and thyroid hormone. Richard S. Saver, Medical
Research and Intangible Harm, 74 U. CIN. L. REV. 941, 977 (2006). Her allegations with regard to the
consent process have implications for research involving pregnant women generally. Id. Her counsel
argued that she suffered from the therapeutic misconception, in part because of class and language
barriers, but also because when her consent was sought she was experiencing a high-risk pregnancy and
had been treated with pain-killing medications. Id. Diaz is noteworthy because it “was likely the first
time research subjects recovered substantial monetary awards in the absence of credible physical injury
claims.” Id. at 978. After extensive discovery, the plaintiffs in Diaz, a certified class of approximately
5,000 pregnant women, settled with the defendant medical center for $3.8 million. Id. The plaintiffs’
novel dignitary harm constitutional claim was central to their success. Id. Ordinary informed consent
and negligence claims would have failed because the plaintiffs and their babies did not receive substandard medical care and could not demonstrate any physical harm. Id.
229. See Miller v. Dacus, 231 S.W.3d 903, 909–10 (Tenn. 2007) (citing cases).
230. 45 C.F.R. § 46.204(d), (e) (2010). Anna Mastroianni points to the Supreme Court’s decision
in UAW v. Johnson Controls, Inc. as further support for the claim “that the informed consent of the
woman will preclude the imposition of liability,” noting that the Court commented in dicta that “‘[i]f,
under general tort principles, Title VII bans sex-specific fetal-protection policies, the employer fully
informs the woman of the risk, and the employer has not acted negligently, the basis for holding an
employer liable seems remote at best.’” Mastroianni, supra note 225, at 180 (quoting UAW v. Johnson
Controls, Inc., 499 U.S. 187, 208 (1991)).
231. T.D. v. N.Y. State Office of Mental Health, 650 N.Y.S.2d 173, 191–92 (N.Y. App. Div.
1996).
232. See Grimes v. Kennedy Krieger Inst., 782 A.2d 807 (Md. 2001).
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regulations governing research in pregnant women similarly do not
allow non-therapeutic research that poses more than a minimal risk to
fetuses. 233
One cannot necessarily conclude from the limited number of lawsuits
that clinical trial sponsors’ potential exposure to liability is limited. Part
or all of the explanation for the dearth of litigation is surely the dearth of
research and development activity. Still, the limited number of
participants in a clinical trial imposes a limit on the trial sponsors’
exposure, and research injuries are not likely to be a significant source
of liability. Even if research does not itself cause or risk causing
physical harm, however, if it is conducted after a drug has been
approved and is being marketed, it creates litigation risk. Should
epidemiological or other research reveal a correlation between ingesting
a company’s drug while pregnant and maternal or fetal harm, some of
the women who ingested the drug and were harmed are likely to sue,
perhaps claiming, as the plaintiff in Kilker did, that the company knew
of the risk before it conducted the research and failed to provide
adequate warnings. 234 GSK, the defendant in Kilker, defended itself at
trial by arguing that when two epidemiological studies showed an
association between Paxil and an increased risk of birth defects, GSK
added the new information to the Paxil label as soon as it could. 235
Today, GSK continues to maintain that Paxil does not, in fact, cause
birth defects. Neither the company’s faith in Paxil’s safety, nor its
timely inclusion of the study results on the Paxil label, was enough for it
to win at trial, although either or both may explain the jury’s decision
not to award punitive damages. 236
Many observers believe that research studying the effects of drugs on
pregnant women and fetuses is especially susceptible to a liability
barrier. In all pregnancies there is a background risk of an adverse
outcome, irrespective of whether the mother took medication.
233. 45 C.F.R. § 46.204(b) (2010).
234. Noah, supra note 34, at 451 (“Courts sometimes struggle to determine precisely when a seller
should have known that its product presented a risk of injury, whether the failure to provide a warning
caused the plaintiff’s injury given the fact that physicians may learn of new risk information from a
variety of other sources, and whether the content and method selected for communicating the
information was adequate in light of limitations in the way health care professionals discover and
assimilate new information.”).
235. Transcript of Closing Statement of Chilton Varner at 117, 127, 145, Kilker v. SmithKline
Beecham Corp. (Pa. Ct. Com. Pl. Oct. 8, 2009) (No. 1813).
236. Kushner, supra note 193, at 541–42 (“[E]ven in the absence of data demonstrating an unsafe
product, pharmaceutical manufacturers are not shielded from products liability or products liability
litigation. Such suits disincentivize pharmaceutical manufacturers from postmarket safety testing
because evidence of safety has little economic value if it does not reduce the costs of litigation and
liability.”).
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Approximately 17% of recognized pregnancies end in a miscarriage,
which is defined for purposes of data collection as fetal death prior to
twenty weeks gestation. 237 Stillbirth, which is defined as fetal death
after twenty weeks gestation, occurs in one in one hundred sixty
deliveries. 238 An estimated 3% of babies are born with major genetic or
structural birth defects. 239 Most miscarriages, stillbirths, and birth
defects occur due to unknown causes. Environmental factors, defined to
include drugs but also, among other things, infectious agents, cause
approximately 10% of birth defects. 240 Another 20% are genetic in
origin. 241 Between 65% and 75% of birth defects are idiopathic, which
means that they have no known cause. 242 Some percentage of the
women whose children suffer from birth defects will blame medication
they took during pregnancy for their children’s injuries and will pursue
litigation. 243
Pregnancy and birth is considered a special case for a second reason:
the potential for large damage awards due to the devastating nature of
birth defects. A baby born with a birth defect may have expensive
special needs for a long lifetime. 244 Damage awards may also be high
because innocent, injured babies are sympathetic plaintiffs.
Finally, pregnancy and birth is considered a special case because of
the “long tail” of associated litigation. In every state a child who is born
237. Ventura et al., supra note 59, at 3, 24. The miscarriage rate for unrecognized pregnancies,
that is, those that begin and end so early in gestation that the woman never knew she was pregnant, is
believed to be much higher. Id. at 24.
238. Press Release, The American College of Obstetricians and Gynecologists, ACOG Issues
New Guidelines on Managing Stillbirths (Feb. 20, 2009), http://www.acog.org/from_home/
publications/press_releases/nr02-20-09-2.cfm.
239. Dept. of Health & Human Servs., Ctrs. for Disease Control & Prevention, Update on Overall
Prevalence of Major Birth Defects – Atlanta, Georgia, 1978–2005, 57 MORBIDITY AND MORTALITY
WEEKLY REP. 1, 2–3 (2008), available at http://www.cdc.gov/mmwr/PDF/wk/mm5701.pdf. See also C.
Irl et al., The PEGASUS Project* – A Prospective Cohort Study for the Investigation of Drug Use in
Pregnancy, 35 INT’L J. CLIN. PHARMACOLOGY & THERAPEUTICS 572, 572 (1997) (“The prevalence of
congenital malformations requiring medical intervention or affecting the quality of life is about 70 per
1,000 births [i.e. 0.7%]. Accounting for approximately one third of all deaths in the first year of life,
they represent the single most frequent cause of infant mortality . . . .” (citations omitted)).
240. Irl et al., supra note 239, at 572.
241. Id.
242. Id.
243. Arthur Allen, Prepare for a Vaccine Controversy, N.Y. TIMES, Aug, 1, 2009, at WK10
(“[P]regnant women will be urged to get the vaccine because doctors have seen how H1N1 can cause
especially nasty infections during pregnancy. But about one in seven pregnancies ends in a miscarriage,
so nearly 1,500 of 10,000 women in early pregnancy will miscarry this fall—whether or not they get the
H1N1 vaccine.”); Elyse Tanouye, Suits Involving Defunct Bendectin Chill Development of Pregnancy
Medications, WALL ST. J., June 22, 1993, at B1 (“[This] is a particularly daunting research area for the
pharmaceutical companies because drugs can both cause birth defects and be blamed for ones that would
have occurred anyway.”).
244. Clayton, supra note 200, at 104.
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alive can assert a claim for harm done prenatally. 245 In most states,
these claims are tolled until the child reaches the age of majority. 246 As
an executive at PhRMA, the trade organization representing most
pharmaceutical and biotechnology companies, told the Wall Street
Journal, drug companies’ research decisions are affected by the prospect
of seemingly unending litigation exposure. 247
There are reasons to question whether any or all of these factors make
liability exposure for research studying the effects of drugs on pregnant
women and fetuses uniquely large, unpredictable, or otherwise
problematic. First, adverse events occur across therapeutic areas. There
is a background risk of disability and death in all populations. Second,
the potential for large damages awards and the long tail of loss obtain in
whole or in part when drugs are developed to treat children. A
legislative carrot-and-stick scheme has effectively incentivized pediatric
drug development; the resultant products liability litigation has not been
of note. Finally, off-label use of medication by pregnant women is
widespread. Litigation has arisen where women and babies have
experienced adverse events, but manufacturers have not been driven into
bankruptcy due to the resultant damage awards.
In the absence of empirical data, it is impossible to know precisely
how manufacturers perceive and weigh the tort system’s competing
incentives in the context of maternal–fetal medication research. What is
clear is that exposure to liability is far from the only driver of company
decision-making. Even if companies’ exposure to liability is, on
balance, a barrier to research, it would not follow that companies are
“ready, willing, and able to conduct socially beneficial research, but for
the costs of liability litigation and awards.” 248
IV. PUBLIC POLICY APPROACHES TO CLOSING THE INFORMATION GAP
A. Relief from Liability for Research
In the pregnancy context and in other contexts where liability
concerns are thought to be particularly salient, there are calls for
relieving companies of the unpredictability of tort liability and
compensating victims in an alternate system. 249
245.
246.
247.
248.

Id.
Id. at 104 n.4.
Tanouye, supra note 243, at B1.
Wendy K. Mariner, Compensation for Research Injuries, in 2 WOMEN AND HEALTH
RESEARCH: ETHICAL AND LEGAL ISSUES OF INCLUDING WOMEN IN CLINICAL STUDIES, 113, 118 (Anna
C. Mastroianni et al. eds.,1994).
249. See, e.g., Editorial, Drug Development for Maternal Health Cannot Be Left to the Whims of
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The highest profile example of such a system is the National Vaccine
Injury Compensation Program (VICP). 250 In the early 1980s, vaccine
manufacturers’ liability exposure was high, and they had difficulty
securing liability insurance. 251 Concerns were raised about the exit of
manufacturers from childhood vaccine production; by the end of 1984,
only one manufacturer of the pertussis vaccine remained. 252 In 1986,
after several attempts, Congress passed the National Vaccine Injury
Compensation Act establishing the VICP. 253 The twin goals of the
VICP are (1) to offer the families of children injured by vaccines a nofault alternative to the tort system that provides prompt and fair
compensation and (2) to protect vaccine manufacturers from the specter
of crippling liability which was threatening the vaccine supply. 254
Claimants may be compensated for their medical expenses, loss of
earning capacity, and reasonable attorney’s fees and costs. 255 Awards
for pain and suffering are capped at $250,000, and punitive damages are
prohibited. 256 If a vaccine causes death, the maximum award to the
estate is $250,000 plus reasonable attorney’s fees and costs. 257 The
program is funded by an excise paid by patients of $0.75 per dose; 258 in
the Market, 5 PLOS MED. 841, 842 (2008) (arguing that any mechanism to encourage “the testing and
collection of data on old and new drugs” in pregnancy would need to “specifically accept liability when
harm occurs”); Lyerly et al., supra note 14 at 17 (recommending that “the liability concerns that animate
so much of the behavior around research and drug development during pregnancy” be addressed at the
federal and state levels); see also, e.g., James M. Wood et al., Product Liability for Stem Cell Research
and Therapies – A Proposal, 18 HEALTH LAWYER 1 (2005) (recommending adoption of an alternative
compensation system for stem cell research); William M. Brown, Déjà Vu All Over Again: The Exodus
from Contraceptive Research and How to Reverse It, 40 BRANDEIS L.J. 1 (2001) (contraceptive
research); Andrew R. Klein, A Legislative Alternative to "No Cause" Liability in Blood Products
Litigation, 12 YALE J. ON REG. 107 (1995) (blood products); Gregory C. Jackson, Comment,
Pharmaceutical Product Liability May Be Hazardous to Your Health: A No-Fault Alternative to
Concurrent Regulation, 42 AM. U. L. REV. 199 (1992) (all drug products); H. William Smith, III, Note,
Vaccinating AIDS Vaccine Manufacturers Against Product Liability, 42 CASE W. RES. L. REV. 207
(1992) (AIDS vaccine).
250. National Childhood Vaccine Injury Act of 1986, 42 U.S.C. § 300aa-34 (2006).
251. Breslow, supra note 194, at 142 n.78 (quoting Wyeth Laboratories executive who testified
before Congress that his company had stopped marketing the diphtheria, tetanus, and pertussis vaccine
“because of extreme liability exposure, cost of litigation and the difficulty of continuing to obtain
adequate insurance”).
252. Notably, before the legislation creating the VICP was enacted, a second manufacturer
resumed manufacturing and distributing the vaccine. Lainie Rutkow et al., Balancing Consumer and
Industry Interests in Public Health: The National Vaccine Injury Compensation Program and Its
Influence During the Last Two Decades, 111 PENN. ST. L. REV. 681, 696 (2007).
253. Id. at 688–703.
254. Id. at 684.
255. 42 U.S.C. § 300aa-15(a), (e)(1)(A) (2006).
256. Id. § 300aa-15(a)(4), (d).
257. Id. § 300aa-15(a)(2).
258. Id. § 300aa-15(i)(2); 26 U.S.C. § 9510(b)(1) (2006); 26 U.S.C. § 4131(a), (b) (2006).

Published by University of Cincinnati College of Law Scholarship and Publications, 2011

41

University of Cincinnati Law Review, Vol. 79, Iss. 1 [2011], Art. 6
GREENWOOD FINAL FORMAT 3

308

2/14/2011 5:48:25 PM

UNIVERSITY OF CINCINNATI LAW REVIEW

[Vol. 79

Fiscal Year 2011 the average award was $1,041,874 plus attorney’s fees
and costs. 259
The first step in the VICP process is filing a petition with the United
States Court of Federal Claims. 260 The Claims Court then forwards the
petition to a VICP special master for decision. 261 Claimants are entitled
to a presumption of causation if they show that they were administered a
vaccine listed on the VICP Vaccine Injury Table and sustained a listed
injury within a specified time period. 262 The table includes, among
others, all vaccines recommended for “routine administration to
children” by the CDC. 263 The government can only avoid compensating
a claimant who suffers a “table injury” by showing that the vaccine did
not in fact cause the injury. 264 Claims for conditions not listed on the
table are evaluated on a case-by-case basis; claimants bear the burden of
establishing that their condition was caused or exacerbated by a covered
vaccine. 265 Claimants are not required to prove that the vaccine
manufacturer or administrator was at fault to recover. 266
The special master’s decision can be appealed to the Claims Court. 267
The decision of the Claims Court can be further appealed to the United
States Court of Appeals for the Federal Circuit, followed by the United
States Supreme Court. 268 Alternatively, after the Claims Court issues its
decision, the claimant can decline any compensation proffered and sue
the vaccine’s administrator or manufacturer directly. 269 Once in court,
the National Vaccine Injury Compensation Act protects vaccine
manufacturers from liability for injuries that are “unavoidable even
though the vaccine was properly prepared and was accompanied by
proper directions and warnings.” 270 They are also protected from
259. Health Res. & Servs. Admin., U.S. Dep’t of Health & Human Servs., Nat’l Vaccine Injury
Comp. Program, Statistics Reports, http://www.hrsa.gov/vaccinecompensation/statistics_report.htm (last
visited Nov. 9, 2010).
260. 42 U.S.C. § 300aa-11(a)(1) (2006).
261. Id.
262. Rutkow et al., supra note 252, at 686 (“For example, a person would be eligible for VICP
compensation if he or she received a measles, mumps, and rubella (MMR) vaccination and experienced
anaphylactic shock zero to four hours later.”).
263. 42 U.S.C. § 300aa-14(e) (2006).
264. Id. § 300aa-11(c)(1); 42 U.S.C. § 300aa-13(a)(1) (2006).
265. Id. § 300aa-11(c)(1)(C)(ii).
266. Rutkow et al., supra note 252, at 684.
267. 42 U.S.C. § 300aa-12(e) (2006).
268. Id. § 300aa-12(f).
269. Id. § 300aa-21.
270. Id. § 300aa-22(b)(1). With certain exceptions
a vaccine shall be presumed to be accompanied by proper directions and warnings if the
vaccine manufacturer shows that it complied in all material respects with all requirements
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liability for failing to warn the injured party directly. 271 Manufacturers
who can show that they complied “with all requirements under the
Federal Food, Drug, and Cosmetic Act and the Public Health Service
Act applicable to the vaccine and related to the vaccine injury or death
with respect to which the action was brought” benefit from a rebuttable
presumption against the award of punitive damages. 272
Childhood vaccines are particularly appropriate for an alternative nofault compensation system which guarantees recovery to victims. It is in
the interest of public health for all or almost all children to be vaccinated
and as a result, inoculation is a condition of entry to daycare and
school. 273
Because population-wide vaccination leads to “herd
immunity,” there are positive externalities to each family’s choice to
vaccinate. 274 Unfortunately, there is also a negative internality.
Vaccination brings with it a small but significant risk of harm, including
anaphylactic shock, seizures, and death in previously healthy
children. 275 Because the number of children vaccinated is so high, the
small risk that a vaccine will cause injury translates into substantial and
predictable population-wide harm. This, in turn, exposes the vaccine’s
manufacturer to substantial and potentially crippling liability.
Research into maternal–fetal medication risk is distinguishable from
mass inoculation in important ways. Even if companies were to adopt
more robust research agendas, the numbers involved would be much
lower than is the case with inoculation. There is little reason to believe
that the resultant liability would be so crippling that an alternative nofault compensation system would be justified.
In its 1994 report Women and Health Research, the IOM explained
that it considered “[t]he question of whether there should be a special

under the Federal Food, Drug, and Cosmetic Act . . . and section 351 of the Public Health
Service Act . . . (including regulations issued under such provisions) applicable to the
vaccine and related to vaccine-related injury or death for which the civil action was
brought[.]
Id. § 300aa-22(b)(2). In October 2010, the Supreme Court heard oral argument in a case in which the
plaintiff has challenged the scope of the National Vaccine Injury Compensation Act’s preemption
provisions. See Posting of Matthew Scarola to SCOTUSblog, http://www.scotusblog.com/2010/10/
argument-recap-court-considers-vaccine-design-defect-liability/ (Oct. 14, 2010, 11:08 AM).
271. 42 U.S.C. § 300aa-22(c) (2006).
272. Id. § 300aa-23(d)(2).
273. Ross D. Silverman, Litigation, Regulation, and Education – Protecting the Public’s Health
through Childhood Immunization, 360 NEW. ENG. J. MED. 2500, 2501 (2009).
274. Anthony Ciolli, Religious & Philosophical Exemptions to Mandatory School Vaccinations:
Who Should Bear the Costs?, 74 MO. L. REV. 287, 297 (2009) (explaining that if a “relatively small
percentage of a religious community’s population” decide against immunization, the negative
externalities could include a loss of herd immunity and a resulting epidemic).
275. Rutkow et al., supra note 252, at 681.
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compensation scheme for injuries sustained by children as a result of a
parent’s participation in a clinical study.”276 The IOM determined that a
special compensation scheme that would cover children harmed
prenatally by experimental drugs taken by their mothers during
pregnancy would be impracticable because of “especially difficult
problems with regard to establishing causation and averting large
numbers of questionable recoveries.” 277 Establishing causation would
be even more problematic if the special compensation scheme were to
cover a company’s exposure to liability from the lawsuits that would
inevitably follow an announcement that maternal-fetal medication
research sponsored by the company had identified a safety concern.
Most importantly, there is little reason to believe that adoption of an
alternative system would induce manufacturers to implement robust
maternal–fetal research agendas. Shortages of childhood and other
vaccines persist. In late 2004, in the wake of an announcement from
Chiron Corporation that it would not be able to provide flu vaccine for
the United States market that year due to manufacturing-related safety
concerns, Congress passed legislation adding the flu vaccine to the list
of vaccines covered by the VICP. 278 Interestingly, while members of
Congress speculated that fear of litigation was driving flu vaccine
manufacturers from the market, adding the flu vaccine to the VICP has
not lead to an increase in manufacturer participation in the flu vaccine
market. Michelle Mello and Troyen Brennan predicted as much in a
2005 article in JAMA, noting that the undersupply problem is complex
and that “the historical record provides cause for skepticism that liability
relief alone will prevent another flu vaccine shortage.” 279
B. Rewarding Research with an Extended Period of Exclusivity
Children and pregnant women are, or were, similarly situated in that
both must contend with a dearth of information about drug efficacy and
safety. Unlike pregnant women and fetuses, children have been the
beneficiary of key legislation designed to end their status as “therapeutic
orphans.” 280 In 1997, Congress enacted the pediatric exclusivity
provision of the U.S. Food and Drug Administration Modernization Act
(FDAMA), which authorized the FDA to extend a drug’s period of
276. INST. OF MED., supra note 146, at 169.
277. Id.
278. Rutkow et al., supra note 252, at 726.
279. Michelle M. Mello & Troyen A. Brennan, Legal Concerns and the Influenza Vaccine
Shortage, 294 JAMA 1817, 1820 (2005).
280. Cohen, supra note 124, at 662 (quoting S. REP. NO. 105-43, at 3 (1997)).
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exclusivity if the drug’s manufacturer agreed to conduct “pediatric
studies,” defined as at least one clinical investigation in children. 281 In
2002, the pediatric exclusivity provision was reenacted as part of the
Best Pharmaceuticals for Children Act (BPCA); 282 the BPCA was
reauthorized in 2007 in Title V of the Food and Drug Administration
Amendments Act (FDAAA). 283
The pediatric exclusivity provision provides that when a drug is still
under a patent or other exclusivity term, a company may be awarded an
additional six months of exclusivity for the entire active moiety—that is,
for all of the drug’s formulations and indications—in exchange for
completing FDA-requested safety, efficacy, or pharmacokinetic
pediatric studies. 284 If the FDA “determines that information relating to
the use of an approved drug in the pediatric population may produce
health benefits in that population,” it may issue a formal request of the
drug’s manufacturer, asking it to conduct the necessary study or
studies. 285 The manufacturer is free to decline the agency’s requests and
is especially likely to do so if a drug is no longer in an exclusivity
period, as there would be no incentive to conduct the research in that
case. 286
Once the study or studies are completed, the FDA decides if
exclusivity is merited. Outcome is irrelevant. There is no requirement
that the studies establish that the drug is safe and effective in children or
even that they generate valuable information about pediatric use.287
Exclusivity is awarded if the studies fairly respond to the agency’s
written request, are conducted in accordance with commonly accepted
scientific principles and protocols, and are properly submitted. 288
Whenever exclusivity is granted, the BPCA requires the FDA to review
all adverse events occurring in children for the next year, as well as all
of the adverse events that occurred in children in previous years; the
results of the review are presented to the FDA’s Pediatric Advisory
Committee, which advises the FDA on whether and how to respond. 289
The FDA is also required to order a labeling change whenever an
agency-requested pediatric study “does or does not demonstrate that the
281. Id. at 663–65.
282. Id. at 667.
283. Food and Drug Administration Amendments Act of 2007, Pub. L. No. 110-85, §§ 501–505A,
121 Stat. 823, 876–89 (to be codified at 21 U.S.C. § 355a).
284. 21 U.S.C.A. § 355a (West 2010).
285. Id. § 355a(c)(1).
286. Cohen, supra note 124, at 666.
287. Eisenberg, supra note 86, at 730.
288. 21 U.S.C.A. § 355a(b)(1), (c)(1) (West 2010).
289. Id. § 355a(l).
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drug that is the subject of the study is safe and effective, including
whether such study results are inconclusive, in pediatric populations or
subpopulations.” 290 The BPCA does not empower the FDA to order
manufacturers to produce and distribute age-appropriate formulations,
even when medicines are found to be safe and effective for use in
children. 291
If a manufacturer chooses not to conduct an FDA-requested study of
an on-patent drug, the FDA may ask whether the Foundation for the
National Institutes of Health (FNIH) has sufficient funding “to initiate
and fund all of the studies in the written request in their entirety within
the timeframes specified within the written request.” 292 If the FNIH has
sufficient funding, the statute requires it to fund the studies. If it does
not, the statute requires the FDA to “consider” whether to exercise its
authority under the Pediatric Research Equity Act (PREA) to require
that the company conduct the study. 293
As of November 30, 2009, the FDA had issued 377 written requests
for pediatric studies of drugs prescribed to children, 306 of which were
issued following a proposal from the manufacturer. 294 By early 2007,
“the program ha[d] generated more than 300 pediatric studies[,]” 295 and
“nearly half of the 10 drugs most frequently prescribed for children” had
“been studied under the BPCA.” 296 While there were only eleven
pediatric labeling changes between 1990 and 1997, there were one
hundred thirty between 1997 and 2007. 297 According to a chart posted
on the FDA’s website, pediatric studies conducted in response to the
agency’s requests had resulted in 184 labeling changes by the end of
2009. 298 However, the authors of a 2007 JAMA article estimated that
only a “third of the labeling changes [since the start of the program]
showed an important difference in the pediatric dosing, safety, or
290. Id. § 355a(j).
291. Id. § 355a(e)(2), (f)(6)(D).
292. Id. § 355a(n)(1)(A).
293. Id.
294. U.S. Food & Drug Admin., Pediatric Exclusivity Statistics as of November 30, 2009,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm050006.htm (last
visited Jan. 7, 2010).
295. Jennifer S. Li et al., Economic Return of Clinical Trials Performed Under the Pediatric
Exclusivity Program, 297 JAMA 480, 480 (2007).
296. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-07-557, PEDIATRIC DRUG RESEARCH: STUDIES
CONDUCTED UNDER BEST PHARMACEUTICALS FOR CHILDREN ACT 5 (2007).
297. Carissa M. Baker-Smith et al., The Economic Returns of Pediatric Clinical Trials of
Antihypertensive Drugs, 156 AM. HEART J. 682, 682 (2008).
298. U.S. FOOD & DRUG ADMIN., PEDIATRIC LABELING CHANGES THROUGH DECEMBER 24, 2009
(2009), http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/
UCM163159.pdf.
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efficacy compared with adult patients.” 299 Even more concerning, a
subsequent study revealed that information on less than half of the
products found to have safety concerns when used by children was
published in the peer-reviewed literature and that close to half of the
articles that were published did not accurately reflect the FDA’s
review. 300
The pediatric exclusivity provision is off-budget, and it is popular
with the innovator drug industry. 301 It is unsurprising that Congress has
reauthorized it three times. Questions have arisen about how effective it
has been at solving the information problem. Some of the drugs studied
are rarely prescribed to children, while important drugs that are offpatent and no longer subject to exclusivity have gone unexamined. 302
Because companies have no incentive to conduct follow-up research,
questions such as why a drug had a higher adverse event rate in children
remain unanswered, and although many pressing questions about
medication use in children can only be answered with epidemiological
research, such studies do not “count” toward exclusivity. Companies
also have an incentive to wait until their drugs are nearing the end of
their patent life to pursue the BPCA’s additional six months of
exclusivity. This is only partially remedied by FDAAA’s requirement
that companies must complete the process at least nine months prior to
the expiration of the existing patent or exclusivity period in order to
qualify for the extension. 303
In addition, many critics of the pediatric exclusivity provision
complain that the benefit to companies of six months of exclusivity
dwarfs the cost of conducting the requisite clinical trials. A 2007 study
evaluated nine drugs, each from a different therapeutic area, for which
pediatric data were submitted from 2002 to 2004. 304 Median cash
inflows were $140 million, while median cash outflows were just $10
million. 305 The median net economic benefit accruing to the drugs’
299. Li et al., supra note 295, at 487. The GAO is more generous, determining that 87 percent of
the drugs granted pediatric exclusivity between 2002 and 2005 had “important labeling changes” as a
result of the studies conducted. U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 296, at 4.
300. Daniel K. Benjamin, Safety and Transparency of Pediatric Drug Trials, 163 ARCHIVES
PEDIATRICS & ADOLESCENT MED. 1080, 1083 (2009).
301. See Programs Affecting Safety and Innovation in Pediatric Therapies: Hearing Before the
Subcomm. on Health of the H. Comm. on Energy and Commerce, 110th Cong. (2007) (Statement of Lori
M. Reilly, Vice President, Policy & Research, Pharmaceutical Research Manufacturers of America),
http://energycommerce.house.gov/images/stories/Documents/Hearings/PDF/110-he-hrg.052207.Reillytestimony.pdf (urging reauthorization of both the BPCA and the PREA).
302. Noah, supra note 28, at 282–83.
303. 21 U.S.C.A. § 355a(b)(2), (c)(2) (West 2010).
304. Li et al., supra note 295, at 481.
305. Id. at 483–84. A 2006 industry survey yielded a higher estimated cost: $20 million to
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manufacturers was $132 million, with a range from -$8.9 million to
$507 million. The authors cautioned that five of the nine drugs studied
were blockbusters, meaning that they had more than $1 billion in sales.
For products with lower sales, the inflow would be lower. 306
A more recent study found that the median cost to evaluate one of
nine hypertension drugs for which completed pediatric study reports
were submitted to the FDA between 1997 and 2004 was $6 million, with
the median cost of clinical trials ($4.3 million) far exceeding that of
bioequivalence
or
bioavailability
studies
($731,856)
and
307
pharmacokinetic studies ($1.1 million).
The after-tax, inflationadjusted median cash outflow to pay for FDA-requested studies was
$4.8 million, while the median cash inflow over the six month
exclusivity period was $60 million. 308 There was a wide range in net
return-to-investment, although in all cases the net return was positive.
Just under half of the drugs studied had a return on the dollar of less than
$10, while just over half had a return of greater than $20. 309
In addition to generating windfall profits for pharmaceutical
companies, the additional six months of exclusivity costs consumers,
especially the elderly, hundreds of millions of dollars by delaying the
launch of cheaper, generic drugs. 310 It also increases costs borne by
health care payors, including the government, which with the advent of
Medicare Part D is paying a larger portion of the country’s medication
costs than ever before. 311 One commenter has argued that it would be
less expensive and more efficient if pharmaceutical companies declined
to perform any pediatric studies in response to the FDA’s requests and
the government conducted them instead. 312 The host of concerns about
the pediatric exclusivity provision’s cost and efficiency make it difficult
to conclude that it should be expanded to include pregnant women and
fetuses.
complete a BPCA written request. Christopher-Paul Milne & Jon B. Bruss, The Economics of Pediatric
Formulation Development for Off-Patent Drugs, 30 CLINICAL THERAPEUTICS 2133, 2138 (2008).
Milne and Bruss point out that the estimates used by Li and his co-authors do not include the cost of
developing pediatric formulations of a drug. Id. They note that multiple formulations may be necessary
to meet the needs of children at various stages of development; they could include “suspensions,
sprinkles, oral solutions, coated granules for reconstitution in water, and adult pumps converted to
deliver smaller doses.” Id.
306. Li et al., supra note 295, at 484–85.
307. Baker-Smith et al., supra note 297, at 685.
308. Id.
309. Id. at 686.
310. Breslow, supra note 194, at 167–69.
311. See THE HENRY J. KAISER FAMILY FOUND., PRESCRIPTION DRUG TRENDS (2010), available
at http://www.kff.org/rxdrugs/upload/3057-08.pdf.
312. Breslow, supra note 194, at 189.
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C. Government-Funded and Government-Mandated Research
The reauthorized BPCA requires that the NIH, in consultation with
the FDA and outside experts, publish a list of the highest priority
diseases or conditions in which medication–related knowledge gaps
negatively affect the children who suffer from them. 313 Funds are to be
awarded
to entities that have the expertise to conduct pediatric clinical trials or
other research (including qualified universities, hospitals, laboratories,
contract research organizations, practice groups, federally funded
programs such as pediatric pharmacology research units, other public or
private institutions, or individuals) to enable the entities to conduct the
drug studies or other research on the issues

on the list. 314 Drugs that are off-patent that the FDA determines should
be studied in children are among those to be included on the list. 315
This is a sensible approach to closing the information gap—albeit one
which critics charge has “never been appropriately funded”—and it
should be extended to include pregnant women for a number of reasons,
the first being that the government can conduct research more cheaply
than it can incentivize research. 316 Also, unlike children, pregnant
women do not typically need drugs to be formulated specifically for
them. Reformulation is one of the central challenges of pediatric
research and one in which the involvement of the manufacturer is
key. 317 In addition, when the government funds research, it does not
need to factor in whether drugs are on- or off-patent or in an exclusivity
period; it does not even need to constrain itself to studies of a single
drug. 318 In the maternal–fetal research arena, the government would be
free to consider whether, instead of a drug by drug effort, it would be
preferable to perform basic research into pregnancy’s pharmacokinetic
and pharmacodynamic effects or into the mechanisms of human

313. 42 U.S.C.A. § 284m (West 2010).
314. Id. § 284m(b).
315. 21 U.S.C.A. § 355a(n)(1)(B) (West 2010).
316. Benjamin, supra note 300, at 1085. Cf. Roin, supra note 89, at 561 (noting the government’s
“history of grossly underfunding clinical research”).
317. Milne & Bruss, supra note 305, at 2138–39 (“[M]anufacturers who attempt to respond to
Written Requests must begin the investigation with a highly resource-intensive, time-consuming, and
risky experiment in formulation development.”).
318. Another way to address this would be to de-link the grant of market exclusivity from a drug’s
patent term, that is, to grant exclusivity to any manufacturer who studied any drug, whether on- or offpatent, in pregnant women. See Roin, supra note 89, at 564 (recommending that Congress authorize the
FDA to reward companies that submit new drug applications for drugs with weak or no patent protection
with periods of exclusivity).
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teratogenicity. 319
Finally, research conducted with government or other noncommercial
support has or should have the advantage of relative trustworthiness.320
Pharmaceutical manufacturers must engage in a constant painstaking
weighing of their duties to shareholders, their common law duties, and
their regulatory obligations. Manufacturers know that if research they
sponsor associates their product with an increased risk of harm, they
could suffer a laundry list of negative sequelae, ranging from being
asked to conduct additional testing or implement marketing restrictions,
to a reduction in sales, to the withdrawal of their product from the
market altogether. Sidestepping the potential conflict between a
manufacturer’s roles as profit-making public company and research
sponsor is an additional benefit of government-funded research. 321
Significant strides have already been made as a result of governmentfunded research. For example, in 2006, grants from the Agency for
Healthcare Research and Quality and from the FDA supported
epidemiological research that revealed that a class of high blood
pressure drugs doctors had long believed to be safe for use in early
pregnancy in fact increased the rate of birth defects. 322 More recently,
319. Cf. Mitchell, supra note 14, at 2557 (“It is a matter of concern that pregnancy registries for
specific drugs, often operated by manufacturers, seek to recruit patients receiving different drugs into
separate registries and a patient receiving multiple drugs into multiple registries. Such competition for
patients and practitioners can and may dilute or fragment the efforts of pregnancy registries that focus on
a wide range of drugs.”).
320. Kevin Outterson, Death from the Public Domain?, 87 TEX. L. REV. SEE ALSO 45, 53 (2009),
http://www.texaslrev.com/sites/default/files/seealso/vol87/pdf/87TexasLRevSeeAlso45.pdf (suggesting
that the benefit of avoiding bias could compensate in whole or in part for any inefficiencies associated
with government funding).
321. This is not to suggest that government-funded research is always free of conflicts of interest.
Notably, investigators who receive government funding to conduct clinical research often have financial
relationships with pharmaceutical companies as well. See, e.g., Letter from Charles E. Grassley,
Ranking Member, U.S. Senate Comm. on Fin., to James W. Wagner, President, Emory Univ. (June 2,
2009), http://s.wsj.net/public/resources/documents/WSJ_LttrEmoryUni_090609.pdf (discussing the case
of Dr. Zachary Stowe, who in 2007 received $154,400 from GlaxoSmithKline, much of it for talks
promoting GSK’s antidepressants, at the same time that he served as principal investigator on several
NIH grants related to antidepressant use by pregnant women). The NIH has announced plans to amend
its conflict of interest regulations to better police these relationships. Responsibility of Applicants for
Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible
Prospective Contractors; Proposed Rule, 75 Fed. Reg. 28,688, 28,689 (May 21, 2010).
322. William O. Cooper et al., Major Congenital Malformations after First-Trimester Exposure to
ACE Inhibitors, 354 NEW ENG. J. MED. 2443, 2448 (2006). In an accompanying editorial, J.M.
Friedman opined as follows:
Clearly, more research on the teratogenic potential of ACE inhibitors in early pregnancy
is needed. This is not the last word on the subject, but it is shocking to realize that it is
almost the first.
....
Not knowing the teratogenic risks of these drugs really does matter. . . . Birth defects
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the CDC-funded National Birth Defects Prevention Study, a multi-site
epidemiological study of women whose pregnancies were affected by
major birth defects, yielded valuable information about two classes of
antibiotics used to treat urinary tract infections, namely that they are
associated with an increased risk of several birth defects when used in
early pregnancy. 323
In an effort to close the information gap, a group of physicians and
ethicists from Duke University, Georgetown University, and Johns
Hopkins University recently started a project called “The Second Wave:
Toward the Responsible Inclusion of Pregnant Women in Research.” 324
While the decision to direct government funds to research benefiting a
particular population or disease, as opposed to funding research
benefiting another population or disease or to funding treatment,
involves a complex weighing of bioethical and social justice
concerns, 325 members of the Second Wave contend that stepping up
research efforts in pregnant women is just because they “have long been
underrepresented in research” and “they and their needs have been
substantially absent from social investments to advance medical
knowledge.” 326 In the summer of 2009, Second Wave advocates
successfully lobbied to have language inserted into the house committee
report accompanying the Departments of Labor, Health and Human
Services and Education Fiscal 2010 Appropriations measure
encouraging the NIH “to expand research on pregnant women with the
goals of better understanding the long-term health effects on women of
disease states in pregnancy, the proper therapeutics for pharmacologic
treatments for pregnant women who face illness, and the safety and
efficacy of medications administered to pregnant women and fetuses.” 327
caused by teratogenic treatments are preventable, and babies and their mothers are being
harmed unnecessarily because we do not know enough about which treatments to use and
which to avoid.
J.M. Friedman, ACE Inhibitors and Congenital Anomalies, 354 NEW. ENG. J. MED. 2498, 2499 (2006).
323. Krista S. Crider et al., Antibacterial Medication Use During Pregnancy and Risk of Birth
Defects, 163 ARCHIVES OF PEDIATRICS & ADOLESCENT MED. 978, 978–79 (2009).
324. The Second Wave: Toward the Responsible Inclusion of Pregnant Women in Medical
Research, http://kennedyinstitute.georgetown.edu/secondwave/; http://www.bioethicsinstitute.org/WEB/
PAGE/901/SECTIONID/379/PAGELEVEL/2/INTERIOR.ASP# (last visited Feb. 23, 2010).
325. Rebecca Dresser, Priority Setting in Biomedical Research, 11 VIRTUAL MENTOR 322, 322–
25 (2009), http://virtualmentor.ama-assn.org/2009/04/msoc1-0904.html.
326. Lyerly et al., supra note 17, at 3. The Second Wave organized a meeting of a group of
experts including government officials in April 2009 “to identify barriers, articulate the costs of
ignorance, and fashion consensus proposals that can immediately begin to make a difference in pregnant
women’s health.” The Second Wave: Toward the Responsible Inclusion of Pregnant Women in Medical
Research, http://kennedyinstitute.georgetown.edu/secondwave/, http://www.bioethicsinstitute.org/WEB/
PAGE/901/SECTIONID/379/PAGELEVEL/2/INTERIOR.ASP# (last visited Feb. 23, 2010).
327. H.R. Rep. No. 111-220, at 136 (2009).
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On December 30, 2009, the FDA announced the creation of the
Medication Exposure in Pregnancy Risk Evaluation Program
(MEPREP). 328 Through MEPREP, the FDA will fund and conduct, in
collaboration with private researchers, “research to study the effects of
prescription medications used during pregnancy.” 329 The participating
sites, which include the HMO Research Network Center for Education
and Research in Therapeutics (CERT), Kaiser Permanente’s multiple
research centers, and Vanderbilt University, “have health care
information for about 1 million births over the past seven years (2001–
2007),” which the researchers will systematically retrieve and
analyze. 330 MEPREP will be led by a steering committee with
representatives from the FDA and from each participating site. 331 In the
press release announcing the program, Commissioner of Food and Drugs
Margaret Hamburg is quoted as follows: “This program is a great
example of FDA and the private sector working together to improve the
health of pregnant women and their children. These data will guide
regulatory policy and influence medical practice.” 332
The FDA’s Sentinel System is another example of a public–private
partnership with the potential to generate valuable information about
maternal–fetal medication risk. Section 905 of FDAAA requires that the
agency establish “a postmarket risk identification and analysis system to
link and analyze safety data from multiple [public and private]
sources.” 333 The statute specifies that the agency’s eventual goal should
be to include data on at least 100 million patients. 334 Once established,
the Sentinel System will allow the FDA “to actively monitor the safety
of medical products continuously and in real-time.” 335 With the
establishment of the System, the FDA will also be well-positioned to
implement the recommendation of Dr. Allen Mitchell of the Slone
Epidemiology Center at Boston University that the agency bring
coherence and organization to the current patchwork of pregnancy
registries (in which pregnant women who are exposed to a medication

328. Press Release, U.S. Dept. of Health & Human Servs., Food & Drug Admin., Health
Organizations to Study Safety of Medications Taken During Pregnancy (Dec. 30, 2009), available at
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm195934.htm.
329. Id.
330. Id.
331. Id.
332. Id.
333. 21 U.S.C.A. § 355(k)(3)(B)(ii) (West 2010).
334. Id.
335. U.S. Food & Drug Admin., FDA’s Sentinel Iniative – Background,
http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149340.htm (last visited May 3, 2010).
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are followed to determine associated outcomes) 336 and case-control
studies (in which women who give birth to babies born with birth
defects are compared to a control group of women whose babies were
born healthy). 337 Finally, if the Sentinel System does not generate
answers to “priority drug safety questions,” including “the safety of use
in domestic populations not included, or underrepresented, in the trials
used to approve the drug (such as . . . pregnant women . . . ),” § 905
authorizes the FDA to contract with an outside entity to conduct a
complementary investigation. 338
Manufacturers should also be required to fund maternal–fetal
medication research in appropriate cases. 339 In the pediatric arena, the
Pediatric Research Equity Act (PREA) requires that, as a condition of
FDA approval of a new drug application or supplemental drug
application for a new active ingredient, new indication, new dosage
form, new dosing regimen, or new route of administration, drugs be
studied in children. Applicants must submit a “pediatric assessment”
which evaluates the drug’s safety and effectiveness for use in children
and “support[s] dosing and administration” for any pediatric subpopulations for which the drug is found to be safe and effective. 340 The
PREA also requires applicants to request approval of the formulations
appropriate for those sub-populations for which the drug is found to be
safe and effective. 341
A deferral provision addresses concerns about delaying drugs’ time to
market. 342 In addition, the pediatric research requirement does not apply
if the “course of the disease and the effects of the drug are sufficiently

336. Angela Scheuerle et al., Measurements of Birth Defect Prevalence: Which Is Most Useful as
a Comparator Group for Pharmaceutical Pregnancy Registries?, 85 BIRTH DEFECTS RESEARCH PART
A: CLINICAL AND MOLECULAR TERATOLOGY 611, 619 (2009) (“Pregnancy registries are designed to
monitor for ‘signals’ of increased risk and to provide reassurance when sufficient unaffected exposed
pregnancies are collected.”); Kristine E. Shields et al., Monitoring Outcomes of Pregnancy Following
Drug Exposure, 27 DRUG SAFETY 353, 353 (2004) (“[T]he strength of the registry lies in its ability to
gather pregnancy outcome reports early in the life of a product and to recognise and analyse unusual
birth defects.”); Dianne L. Kennedy et al., Pregnancy Exposure Registries, 27 DRUG SAFETY 215, 218
(2004) (noting that registries are “seriously constrained” in their ability to detect modest increases in risk
in the range of two to five-fold).
337. Mitchell, supra note 14, at 2558.
338. 21 U.S.C.A. § 355(k)(4)(D)(i)(II)(bb) (West 2010).
339. Human Rights Council, Report of the Special Rapporteur on the Right of Everyone to the
Enjoyment of the Highest Attainable Standard of Health, Paul Hunt, Annex, Mission to
GlaxoSmithKline, ¶ 40, U.N. Doc. A/HRC/11/12/Add.2 (May 5, 2009) (prepared by Paul Hunt)
(“Pharmaceutical companies also have a responsibility to ensure that medicines are developed
for . . . pregnant and lactating women . . . .”).
340. 21 U.S.C.A. § 355c (a) (West 2010).
341. Id. § 355c (d).
342. Id. § 355c (a)(3).
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similar in adults and pediatric patients [such] that pediatric effectiveness
can be extrapolated from adequate and well-controlled studies in adults,
usually supplemented with other information obtained in pediatric
patients, such as pharmacokinetic studies.” 343 The FDA can also waive
the pediatric research requirement, if (1) the “necessary studies are
impossible or highly impracticable,” (2) there is evidence strongly
suggesting that the drug would be ineffective or unsafe in children, or
(3) the drug “does not represent a meaningful therapeutic benefit over
existing therapies for pediatric patients” and “is not likely to be used in a
substantial number of pediatric patients.” 344 A partial waiver can be
granted on the same grounds and “on the ground that it is not possible to
develop a pediatric formulation.” 345
The PREA also empowers the FDA to require that a manufacturer
study one of its already-approved drugs, if the manufacturer declines to
study the drug voluntarily pursuant to the BPCA and the FNIH lacks
funds to conduct the study, under the following circumstances: (1) the
drug is taken by a substantial number of children for the labeled
indications and adequate labeling could benefit pediatric patients; (2)
there is reason to believe the drug would be a meaningful improvement
over existing therapies for children for one of the labeled indications; or
(3) the absence of adequate labeling could pose a risk to pediatric
patients. 346 As of December 24, 2009, the labels of 121 medications had
been changed as a result of studies submitted pursuant to PREA. 347
The PREA should be extended to benefit pregnant women and
fetuses, as well as children. While the provision that manufacturers first
be afforded the opportunity to conduct maternal–fetal research
voluntarily in exchange for an additional period of exclusivity would not
apply, the requirement that FDA seek funding from the FNIH before
ordering a manufacturer to study an already-approved drug could. In
addition, the same or similar exception and waiver provisions that are in
place for the pediatric research requirements could be made available for
maternal–fetal research. Also serving to mitigate any hardship to
manufacturers would be the ability of the FDA to grant a deferral of the
required research until after a new drug is approved for any “appropriate

343.
344.
345.
346.
347.

Id. § 355c (a)(2)(b).
Id. § 355c (a)(4).
Id.
Id. § 355c(b).
U.S. FOOD & DRUG ADMIN., DEP’T OF HEALTH & HUMAN SERVS., PEDIATRIC LABELING
CHANGES THROUGH DECEMBER 24, 2009 (2009), http://www.fda.gov/downloads/ScienceResearch/
SpecialTopics/PediatricTherapeuticsResearch/UCM163159.pdf.
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reason.” 348 In its draft Guidance for Industry on complying with the
PREA, the FDA:
recognizes that in certain cases scientific and ethical considerations will
dictate that pediatric studies should not begin until approval of the drug or
biological product for use by adults—for example, where a product has
not shown any benefit over other adequately labeled products in the class,
the therapeutic benefit is likely to be low, or the risks of exposing
pediatric patients to the new product may not be justified until after the
product’s safety profile is well established in adults after initial
marketing. 349

These considerations apply to maternal–fetal research as well.
Even if the PREA is not extended, the FDA can and should make full
use of its power to require, where appropriate, the establishment of a
pregnancy registry and a plan for pregnancy-related post-marketing
surveillance as conditions of approval. 350
In addition, FDAAA
authorizes FDA to require post-marketing studies and clinical trials
where necessary to: (1) assess a known serious risk of a drug; (2) assess
signals of serious risk; and (3) identify unexpected serious risks where
the data indicates the potential for such risks. 351 In a draft Guidance for
Industry issued in July 2009, the FDA gave as an example of a postmarketing requirement under FDAAA a clinical trial designed to
evaluate the safety of a drug in pregnant women. 352 Notably, FDAAA
does not authorize the FDA to require companies to conduct clinical
trials designed to study products’ efficacy. In the draft Guidance, the
FDA notes that efficacy trials would be considered for agreed-upon
post-market commitments, as opposed to agency-mandated
requirements. 353 Before FDAAA, the FDA entered into voluntary
agreements with manufacturers to conduct post-market trials and
studies, but companies routinely failed to follow through on their
348. 21 U.S.C.A. § 355c(a)(3) (West 2010).
349. OFFICE OF THE COMM’R, U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: HOW TO
COMPLY WITH THE PEDIATRIC RESEARCH EQUITY ACT 9 (2005).
350. PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 727 (3rd ed. 2007) (explaining that
while the FD&C Act does not explicitly authorize the FDA to condition approval on a commitment to
conduct postapproval testing, the agency has been doing so since the 1960s); Kennedy et al., supra note
336, at 218 (“When the purpose of the pregnancy exposure registry is to assess margins of safety of a
product or to monitor for potential harm, it is appropriate to initiate the registry as soon as possible, such
as at the time of initial marketing, when a new indication is approved, or when patterns of use reveal that
the product is used by women of reproductive age.”).
351. 21 U.S.C.A. § 355(o)(3)(B) (West 2010).
352. OFFICE OF THE COMM’R, U.S. FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY:
POSTMARKETING STUDIES AND CLINICAL TRIALS – IMPLEMENTATION OF SECTION 505(O) OF THE
FEDERAL FOOD, DRUG, AND COSMETIC ACT 7 (2009).
353. Id. at 8.
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commitments. 354 FDAAA creates a standard process and timeframe for
negotiating post-marketing requirements and agreed-upon commitments
and authorizes the FDA to track companies’ progress using a timetable
for completion and periodic reports. 355 FDAAA also provides for fines
for non-compliance; 356 previously, the FDA’s formal enforcement
arsenal was limited to the drastic remedy of withdrawal of approval. 357
V. CONCLUSION
Real moral and scientific conundrums arise in maternal–fetal
medicine. There will always be information that is out of reach because
it can only be gleaned from clinical trials that are scientifically
impossible, ethically inappropriate, or financially unjustifiable. The
information gap is deeper and wider than that, however. Ruth Faden,
director of the Berman Institute of Bioethics at Johns Hopkins
University and a leader of the Second Wave movement, describes it this
way: “Everyone thinks, Oh, my God, research on pregnant women! All
kinds of ethical flags go up. We don’t have to start with high drama.
[There’s enough] low-hanging fruit that we could keep lots of medical
researchers busy for a long time.” 358
Because maternal–fetal medication research is underproduced by the
private market, government intervention is warranted. The most direct
approach—government-funded research and government-mandated
research—is likely to be the most effective and efficient. Eliminating
the liability barrier facing pharmaceutical companies is unlikely to be
effective, while offering an extended period of exclusivity as a
“voluntary incentive” to private-sector research is grossly inefficient.
Increased funding of public-private partnerships like MEDREP
combined with increased responsibility on the part of drug companies to
research their products, not just in children but in pregnant women and
fetuses as well, are promising approaches to providing pregnant women
with the data they need to reason well about the daunting questions they
face when illness strikes.
354. See, e.g., Report on the Performance of Drug and Biologics Firms in Conducting
Postmarketing Commitment Studies; Availability, 72 Fed. Reg. 5069, 5070 (Feb. 2, 2007) (reporting
that 37% of new drug applications and abbreviated new drug applications and 47% of biologics license
applications had “open postmarketing commitments with annual reports due, but not submitted within
60 days of the anniversary date of U.S. approval.”).
355. 21 U.S.C.A. § 355(o)(3)(E) (West 2010).
356. Id. § 333(f)(4)(A).
357. HUTT ET AL., supra note 350, at 727.
358. Bonnie Rochman, The Risks (and Rewards) of Pills and Pregnancy, TIME, June 8, 2009,
available at http://www.time.com/time/magazine/article/0,9171,1901482-1,00.html.
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